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Nasal high flow (NHF) therapy is a recent form of non-invasive respiratory support for patients 
suffering from respiratory distress that supplies high flows of heated and humidified air, oxygen or a 
mix via a nasal cannula. A number of in vivo studies have proven its effectiveness at improving blood 
oxygenation; however, its mechanisms of action remain widely unproven. Two proposed mechanisms 
of action, the CO2 washout of anatomic dead space and the production of positive airway pressure, are 
investigated in this thesis for the use of the Fisher & Paykel Healthcare Ltd (FPH) Optiflow™ adult 
nasal cannula through a range of experiments.  
Five anatomically correct upper airway models produced from computed tomography (CT) scan data 
via 3D printing were employed during in vitro experiments and two live subjects participated in in 
vivo measurements. The human respiratory system was faithfully replicated for CO2 washout 
experiments with physiological CO2 diffusion into the lung replicated by a constant flow of CO2 into 
the lung pump. In vivo measurement of a natural breathing flow pattern was scaled to an average 
population tidal volume and respiratory rate for in vitro use.  
In vitro measurements of static pressure during natural breathing found similar flow resistances across 
the nasal passage for inspiratory and expiratory flow directions; however, across the entire upper 
airway greater resistance was seen for inspiration. Introduction of NHF therapy produced significant 
increases in all mean and peak airway pressures within the upper airway with a flow rate of 30 LPM 
fulfilling the inspiratory work requirements presented by the upper airway resistance.  
In vivo and in vitro hot wire anemometry measurements at the exterior nares indicated low velocity 
and turbulence intensity flows at peak inspiration and a high velocity jet with high turbulence during 
peak expiration. At natural breathing an in vitro anterior-posterior velopharynx traverse captured low 
turbulence intensities during peak inspiration and high turbulence intensities during peak expiration. 
Introduction of NHF therapy had little influence on the turbulence intensity profile of peak expiration 
yet did cause significant increases in the turbulence intensities during peak inspiration.  
Measurements of the CO2 concentration near the lung volume over many breath cycles were used to 
find time-averaged CO2 concentrations. For the standard airway model an average CO2 concentration 
of 4.88 ± 0.07 %V/V was determined during natural breathing. Implementation of increasing levels of 
NHF therapy generated significant washout of CO2 reducing this average concentration to a minimum 
of 3.81 ± 0.11 %V/V at a flow rate of 80 LPM. It was determined that airway geometry significantly 
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Nasal high flow (NHF) is a relatively new therapy employed by clinicians to aid patients suffering 
from mild to moderate respiratory distress as an alternative to face mask oxygen therapy and other 
non-invasive therapies. NHF describes the method of supplying high flows of warmed and humidified 
air, oxygen or an air-oxygen mix to a patient via a nasal cannula as a means of increasing the fraction 
of oxygen in the inspired gas (FiO2) and subsequently the oxygen saturation of the patient’s blood. 
The Optiflow™ nasal cannula is designed specifically for the delivery of NHF therapy by Fisher & 
Paykel Healthcare Ltd (FPH). 
1.1 NHF Therapy Mechanisms of Action 
Most previous research into the use of NHF therapy has been focused on monitoring patient outcomes 
during therapy and comparing these to the outcomes from more established therapies such as high 
flow face mask oxygen therapy. NHF has been demonstrated to improve blood oxygenation in critical 
care patients (Chatila et al., 2004, Nicolet et al., 2011, Parke et al., 2011b, Rello et al., 2012, Sztrymf 
et al., 2011, Tiruvoipati et al., 2010) but as it is still a relatively new therapy the means by which it 
does so are still uncertain. It has been proposed by Dysart et al. (2009) that there are five major 
mechanisms of action which make NHF an effective therapy. These five mechanisms are described 
as: 
1. Nasopharyngeal dead space washout due to flushing effect of high flow; 
2. Work of breathing reduction during inspiration due to positive flow pressure; 
3. Improved pulmonary conductance due to warmed and humidified air being supplied in 
comparison to the cold, dry air used in other therapies; 
4. Reduced metabolic effort due to warmed and humidified air supplied; 
5. Improved lung recruitment due to positive pressure provided by high flow. 
Investigation of the first two of these mechanisms is undertaken in this research. 
1.2 Optiflow™ Nasal Cannula 
The Optiflow™ nasal cannula is manufactured by Fisher & Paykel Healthcare Ltd, Auckland, New 
Zealand, and was first introduced to the market in 2006. It is available in three different sizes to suit a 
range of adults. Many factors of the original Optiflow™ Nasal cannula design were chosen to 
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optimise patient comfort rather than therapy efficacy and since its release the design has not been 
altered. The Optiflow™ nasal cannula is recommended for delivery of NHF therapy flow rates from 
10 to 60 LPM. 
1.3 Research Objectives 
This research focused predominantly on confirming the first mechanism of action proposed by Dysart 
et al. (2009), nasopharyngeal dead space washout, but was expanded to include washout of the entire 
anatomic dead space. To this effect the primary objective of this study was to quantify the level of 
CO2 washout achieved by the current Optiflow™ nasal cannula design for a number of NHF flow 
rates through in vitro experimentation. In addition, the influence of variations in upper airway 
geometry on the therapy efficacy was examined. Local static pressure, velocity and turbulence effects 
within the upper airway are also investigated to compliment the washout investigations as well as 
feeding into knowledge for the second mechanism. 
1.4 Thesis Structure 
This thesis encompasses the development of experimental methods and systems through to the 
experimental results and implications and is structured as follows. Chapter 2 provides background on 
the respiratory system anatomy and physiology, the use of NHF therapy and the Optiflow™ nasal 
cannula to provide respiratory support and the theories supporting the first of the two proposed 
mechanisms of action. A review of the current literature related to the objectives of this study is given 
in Chapter 3. Chapters 4, 5 and 6 detail the development and evolution of the upper airway models, 
experimental systems and breath patterns employed in the various experiments throughout this 
research. Chapters 7, 8 and 9 are dedicated to the three major areas experimentally examined; that is 
the upper airway static pressures, upper airway velocities and turbulence intensities, and anatomic 
dead space washout; with each containing the experimental methods, results, analyses and 




2 Background Theory 
2.1 Anatomy of the Respiratory System 
In human anatomy specific terms are used to describe locations and directions without reference to the 
body’s orientation in space; that is, independent of whether the person is standing, sitting or lying, and 
independent of which way they are facing. A brief description, with reference to the illustration of 
Figure 1, of these definitions is necessary so that some of the terms used in this research can be 
understood. Firstly, from a person’s centre, the direction toward their front is referred to as anterior 
while posterior describes the opposite direction, toward the persons back. A plane which intersects the 
person normal to a line running anterior to posterior is referred to as a coronal or frontal plane. Again 
from the persons centre, the direction toward the head is superior and the direction toward the feet is 
inferior. A plane intersecting the person normal to a line running superior to inferior is known as a 
transverse plane. A line drawn down the centre of a person’s front from head to toe is known as the 
midline. As either side of the midline is almost a mirror image the other, slightly different directional 
terms are used for this third axis. Toward the midline is considered medial, whilst the directions away 
from the midline are lateral. A plane intersecting a person normal to medial-lateral axis is known as a 
sagittal plane. A sagittal plane which runs directly through the midline of a person is considered a 
midsagittal plane. 
The respiratory system as illustrated in Figure 2 is comprised of two major regions, designated as the 
conducting airways and the respiratory zone. The conducting airways are all regions of the airway 
from the nostrils down to the terminal bronchioles. These conducting airways serve the purpose of 
filtering, heating and humidifying the inspired air and directing it into the respiratory zone within the 
lungs. The respiratory zone is comprised of the respiratory bronchioles, alveolar ducts, alveolar sacs 
and the alveoli. It is within the respiratory zone that the process of pulmonary respiration occurs, that 





Figure 1: Illustration of the anatomical planes and directions employed (adapted from cnx.org). 
 




Figure 3: Illustration of the regions of the upper airway (adapted from www.gru.edu). 
The upper region of the conducting airways is a combination of complex structures which include the 
nasal vestibules, nasal cavity, nasopharynx, oropharynx and laryngopharynx as shown in Figure 3. 
The nose is a cartilaginous structure which forms the entrance to the upper airways via the nostrils, or 
nares. Within each side of the nose there is a small volume known as the nasal vestibule, each of 
which are lined with fine hairs, vibrissae, which aid in filtering inspired air. At their posterior, the 
passage through each nasal vestibule contracts to a minimum cross section known as the nasal valve, 
followed by a sudden expansion into the nasal cavity. The nasal cavity is separated into right and left 
sides by the nasal septum. The nasal septum is composed of both cartilage and bone, beginning within 
the nose and extending to just anterior of the nasopharynx. Each left and right volume of the nasal 
cavity is divided into superior, middle and inferior regions known as meatuses by three bone 
structures, the turbinates or conchae. These three turbinates are, like the meatuses, referred to as 
superior, middle and inferior and protrude from the lateral nasal cavity walls, stopping short of the 
nasal septum. The turbinates, which increase the internal surface area of the nasal cavity, are covered 
in a highly vascularised, thin mucous membrane which serves to heat and humidify air on inspiration 
and recover heat and humidity from the air on expiration (Elad et al., 2008, Ritter, 1970). A cross 
section of the left and right nasal cavities, showing the turbinates and meatuses is given in Figure 4. 
The upper most surface of each nasal cavity side contains the olfactory receptors, the structures 
responsible for sensing smell, within the olfactory region. 
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Figure 4: Cross section of airway 06B left and right nasal cavities. 
The nasopharynx is the first and most superior of the four sections which constitute the pharynx as 
shown in Figure 3. The nasopharynx connects to the posterior of the nasal cavity and extends down to 
the most inferior location of the uvula, or soft palate. A transition from the nasopharynx into the 
oropharynx occurs at this location of the soft palate, a region referred to as the velopharynx. The 
velopharynx is significant as, aside from the nasal valves, it is the point in the upper airway with the 
smallest cross-sectional area (hence the region of highest velocity in the pharynx during mouth-closed 
breathing). The oropharynx continues down until the epiglottis is reached. The oral cavity connects to 
the anterior of the oropharynx; however, during nasal breathing the oral cavity is most often cut off 
from the pharynx as the tongue rests against the palate, isolating it from the rest of the upper airway 
(Lumb, 2010). At the epiglottis the oropharynx merges into the laryngopharynx, the third and most 
inferior of the three pharynx regions. The laryngopharynx is the most inferior region of the airway 
which also acts as a digestive pathway, with the oesophagus and larynx both branching off at its most 
inferior opening. It is at this point of bifurcation that the epiglottis has an active role, moving down to 
close off the larynx from the laryngopharynx during the act of swallowing to prevent the entry of any 
food or liquids into the lungs. In its natural position the epiglottis is orientated in an superior direction, 
lying close to the posterior of the tongue, but on swallowing the pharynx moves upwards and the 
epiglottis downwards to occlude the entrance to the larynx. The larynx connects the laryngopharynx 
with the trachea and is the region of voice production, containing the vocal chords. The trachea is a 
long, circular passage with a diameter of approximately 25 mm which runs along the anterior of the 
neck and into the thoracic cavity where it bifurcates into the left and right bronchi at a position just 
below the top of the two lungs. These bronchi then enter into the respective left and right lungs and 
further branch into secondary and tertiary bronchi, bronchioles and terminal bronchioles, providing 
passageways to all areas of the lungs. The many branches from the bronchi to the terminal bronchioles 
are collectively known as the bronchial tree. It is after the terminal bronchioles that the volumes 
become active, with respiration occurring within the many alveoli. Respiratory gases fill the alveoli 
which are surrounded by pulmonary capillaries on the other side of the alveolar walls. Where the wall 
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of a capillary meets an alveolar wall a respiratory membrane is formed. It is across this membrane that 
the exchange of oxygen into and carbon dioxide out of the pulmonary blood occurs. This process is 
driven by partial pressure gradients across the membrane which induce passive diffusion of the two 
gasses. 
2.2 Respiratory Physiology 
Respiratory ventilation is the process of gas exchange into and out of the lungs, facilitated by the act 
of breathing. The breathing response can be controlled either consciously or subconsciously, the latter 
of which is the primary mechanism. There are two parts to a breath cycle, the active inspiration and 
the passive expiration. During inspiration the contraction of the diaphragm muscle and other thoracic 
muscles causes an increase in the volume of the thoracic cavity. This results in a pressure decrease 
within the lungs and an influx of air through the airways to equalise the pressure between the lungs 
and the external environment. On expiration these muscles relax and the lungs shrink back to their 
original volume, expelling the inspired volume of air. The contraction of muscles during inspiration 
requires physical effort which contributes to the work of breathing; however, this effort is stored in 
the elastic muscles and on expiration is released to return the lungs to their original condition. The 
conducting airways also contribute to the work of breathing as wall friction causes a resistance to flow 
which results in viscous pressure losses along its length in both inspiratory and expiratory flow 
directions. Expiration can also be forced with the active use of abdominal and internal intercostal 
muscles when the resistance to flow is too high to be overcome by the elastic forces. 
The volume of air exchanged within a breath cycle is known as the tidal volume, and the frequency of 
breaths is the respiratory rate measured in breaths per minute. The minute volume or minute 
ventilation is the volume of air exchanged by the lungs within a minute and is the product of the tidal 
volume and respiratory rate. Average adult tidal volume and respiratory rate are often stated as 500 ml 
and 12 breaths per minute respectively, equating to a minute volume of 6 litres per minute (Tortora 
and Derrickson, 2006, Widmaier et al., 2011). Even at the end of expiration the lungs retain some 
residual volume of gas to maintain patency of the lung structures allowing continuous gas exchange. 
The volume of air which remains in the lungs at the transition between expiration and inspiration is 
the functional residual capacity (FRC) which, for an average adult, has a value of 2.4 litres(Tortora 
and Derrickson, 2006). This volume can be further divided into two more which are the expiratory 
reserve volume, the maximum volume that can be forcefully expired, and the residual volume, what 
remains of the FRC following a forced expiration. The inspiratory capacity is the maximum volume in 
excess of the FRC that can be inspired and is the sum of the tidal volume and the inspiratory reserve. 
The vital capacity of the lungs is the total volume of air that can be exchanged when inhaling the 
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maximum amount after a forced expiration. When this is summed with the residual volume you have 
the total lung capacity. Figure 5 provides an overview of all lung volumes and capacities. 
Figure 5: Illustration of lung volumes and capacities (adapted from cnx.org). 
As pulmonary respiration only occurs within the respiratory zone, the volume of air contained within 
the conducting airways does not participate in the gas exchange process. The conducting airways can 
therefore also be referred as the anatomic dead space, a volume which at the end of expiration 
contains lung gases high in CO2 and at the end of inspiration contains fresh air. Because the dead 
space is filled with these high CO2 concentration gases at the end of expiration, this volume is re-
breathed into the lungs at the beginning of the subsequent inspiration and the same volume of fresh air 
remains in the dead space at its conclusion, not reaching the lungs. This means that the tidal volume 
drawn into the lungs is comprised of both expiratory gases and fresh air. The rate at which fresh air is 
delivered to the respiratory zone is referred to as the alveolar ventilation which, though similar to the 
minute ventilation, subtracts the dead space volume from the tidal volume prior to multiplication with 
the respiratory rate. When a person is suffering from respiratory distress, their tidal volume often 
decreases. To account for this decrease in tidal volume, the respiratory rate must increase so that 
equilibrium of pulmonary respiration can be maintained within the lungs. Because of the expiratory 
gas retention within the dead space the respiratory rate must increase so that the minute volume is 
actually larger than it would be during normal breathing, as a larger percentage of each breath is made 
up of the re-breathed dead space gases. To obtain this higher minute volume requires extra metabolic 
effort which in turn can be detrimental to the health and recovery of the sufferer. The use of NHF 
therapy is aimed to reduce stress on the respiratory system by introducing a continuous high flow of 
heated and humidified air, oxygen or a mix of the two into the airway through the nares. 
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2.3 Nasal High Flow Therapy and the Optiflow™ Nasal Cannula 
NHF therapy is a relatively new breathing therapy with the first adult NHF cannulae introduced in 
2000 (Ward, 2013). Since introduction, NHF has proven to be an effective method of delivering 
oxygen to critical care patients and improving blood oxygen saturation (Chatila et al., 2004, Nicolet et 
al., 2011, Parke et al., 2011b, Rello et al., 2012, Sztrymf et al., 2011, Tiruvoipati et al., 2010). NHF 
therapy has also been shown to provide improved patient comfort when compared to full face mask 
therapy methods, which in turn promotes better patient compliance to the therapy regime (Nicolet et 
al., 2011, Spentzas et al., 2009, Tiruvoipati et al., 2010). The Optiflow™ nasal cannula is designed 
and manufactured by FPH specifically for delivery of NHF therapy.  
  
Figure 6:Comparison of the cannula design differences between the (a) FPH Optiflow™ nasal cannula; 
and (b) Vapotherm High Flow Therapy Interface (adapted from www.vtherm.com). 
NHF therapy is the name used to describe the delivery of high flows of either air, oxygen or an air-
oxygen mix into the airway via a nasal cannula. Therapy delivery via a nasal cannula provides greater 
comfort and freedom to the wearer in comparison to mask administered therapies as it allows them to 
move, talk, eat and drink without disturbing the interface. While most other cannulae have a basic 
form similar to low flow nasal cannulae the Optiflow™ nasal cannula is uniquely designed to 
maximise patient comfort. The soft, flexible Optiflow™ cannula manifold is made to rest on the 
patient’s upper lip with the prongs extending into the nasal vestibules and is secured in place by an 
over-the-ears elastic band. The flow is delivered to the cannula via a single flexible tube as depicted in 
Figure 6 (a). A competitor’s product, designed to be worn with the flow delivery tubes passing over 
the ears for cannula location, is pictured in Figure 6 (b). The Optiflow™ cannula is currently used to 
deliver therapy flows ranging from 10 to 60 litres per minute, well above the minute volume of the 
average person of approximately 6 litres per minute (Tortora and Derrickson, 2006). Before the flow 
is delivered to the patient, it is heated to an optimal temperature of 37°C and humidified to 100% 
relative humidity (44 mg/l). This pre-conditioning is advantageous as gases entering the respiratory 
system must be heated and humidified in the upper airway to prevent dehydration of the lungs and 
airways. If the additional air provided at these high flow rates is not preconditioned, the upper airway 
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is unable to condition it adequately and the airways quickly become stripped of moisture causing the 
wearer great discomfort and, if used for long periods, damage to the airway tissues. 
Mechanisms of Action 
The mechanisms by which NHF therapy is able to effectively improve blood oxygenation are still 
relatively un-researched, though five main mechanisms of action have been put forward by Dysart et 
al. (2009) as previously stated. The first of these two proposed mechanism, dead space washout of 
CO2 and reduction of inspiratory work due to generation of positive airway pressure (PAP), have been 
investigated through this research and their theories are further explained below. 
The first of the five mechanisms is the washout of CO2 from the anatomic dead space. Dysart et al. 
(2009) proposed that the introduction of high flow rates of air into the airway via NHF produces a 
continuous flushing effect, forcing respiratory gases high in CO2 out of the airway. The flushed 
volumes would then be filled with the NHF gases which have very low CO2 concentrations and, in the 
case of delivery of oxygen or an air-oxygen mix, a high concentration of O2. This could effectively be 
considered to constitute a reduction in the dead space volume, as a portion of the volume which would 
be filled with high CO2 gases during expiration while breathing naturally is instead flushed out and 
filled with NHF gases. Subsequently, when NHF therapy is in use the NHF gases (air, pure oxygen or 
an air-oxygen mix) are nearer the lungs at the beginning of each inspiratory breath and therefore 
represent a higher percentage of the tidal volume. For patients suffering from respiratory distress 
while breathing unassisted, implementation of this therapy is believed to aid in increasing the 
respiratory ventilation and thus blood oxygenation. This is thought to lead to beneficial reductions in 
both the respiratory rate and stress on the respiratory system, supporting patient recovery.  
The second mechanism of action proposed by Dysart et al. (2009) is the generation of PAP leading to 
a reduction in inspiratory work. The generation of PAP is the basis of another non-invasive ventilation 
therapy known as continuous positive airway pressure (CPAP). PAP is generated with CPAP by 
supplying high pressure flows to the airways via a sealed mask. By providing PAP the physical effort 
required to overcome the airway resistance during inspiration is reduced, lung recruitment is 
improved and the risk of airway collapse decreased. Dysart et al. (2009) suggests that NHF therapy 
also generates some level of  PAP, thus providing the user with beneficial pressure effects similar to 




3 Literature Review 
This chapter provides a review of literature in the field of in vivo, in vitro and computational fluid 
dynamics (CFD) studies of flows within nasal passage and upper airway geometries as relates to the 
objectives of the current research. It is structured in the same manner as the rest of this thesis such that 
the methods of modelling the airway geometry and defining and delivering the flows are first 
reviewed; followed by consecutive examinations of the in vivo, in vitro and CFD studies carried out 
for upper airway pressures, upper airway flow patterns and turbulence, and the use of NHF therapy 
and CO2 washout of anatomic dead space. 
3.1 Nasal Cavity and Airway Modelling for In Vitro and CFD Studies 
In the many previous in vitro and CFD studies of flows within the nasal cavity and upper airways 
numerous approaches have been taken to produce or define the desired flow domain. In the case of in 
vitro experiments replication of a physiologically accurate nasal cavity or upper airway is challenging 
and is often accomplished by first extracting the desired geometry from MRI (Grgic et al., 2004, 
Häußermann et al., 2002, Schreck et al., 1993) or CT (Doorly et al., 2008a, Grgic et al., 2004, Hahn et 
al., 1993, Hopkins et al., 2000, Janssens et al., 2001, Kelly et al., 2000, Kim and Chung, 2004, Kook 
Kim et al., 2006, Mylavarapu et al., 2009, Spence et al., 2012) scan data. Airway meshes used to carry 
out CFD simulations are almost exclusively derived from MRI or CT scan data (Croce et al., 2006, 
Gambaruto et al., 2009, Ishikawa et al., 2006, Jeong et al., 2007, Pantle et al., 2010, Stringer et al., 
2010, Tan et al., 2012, Wen et al., 2007). Once a digital airway surface has been extracted and 
extraneous geometrical features have been removed it can be modified or simplified if desired as in 
the cases of Doorly et al. (2008a), Grgic et al. (2004), Hörschler et al. (2006) and Kook Kim et al. 
(2006). CFD meshes and physical models can subsequently be derived from the digital airway 
surface. The use of scan data to produce meshes and physical models is associated with some issues. 
In some cases the scan data used is low resolution with scan planes 1 to 5 mm apart which can result 
in inadvertent simplification of the intricate airway geometry. Care must be also taken during airway 
surface extraction from the scan data as it is possible for the anatomy to be incorrectly defined as 
seems to be the case for the airway of Jeong et al. (2007) in which the superior regions of the left and 
right sides of the nasal cavity are connected. As CT and MRI scans are employed to identify the 
presence of disease it is uncommon for an entire, healthy upper airway to be captured which can limit 
the flow domain available.  
Physical models developed for in vitro experiments by Hahn et al. (1993) and Schreck et al. (1993) 
used equally spaced cross-sections of the airway scans as templates from which sections of the airway 
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were cut out of plates of Styrofoam and acrylic, respectively, then assembled in order to form the full 
volume. Recently it has become more common to use 3D printing methods to form physical models 
from the digital airway surfaces, either by direct printing (Grgic et al., 2004, Janssens et al., 2001, 
Mylavarapu et al., 2009) or by printing the airway as a dissolvable solid, or ‘negative’, that is cast in 
silicone and then dissolved (Doorly et al., 2008a, Hopkins et al., 2000, Hörschler et al., 2006, Kelly et 
al., 2000, Kim and Chung, 2004, Kook Kim et al., 2006, Spence et al., 2012). The use of cadavers to 
form airway models has become rare in recent years as post-mortem the airway surface loses 
moisture, particularly in the highly vascular mucous membrane covering the nasal cavity walls, 
causing an increase in patency. Nevertheless an airway model was produced by the plastination of a 
cadaver head for the work of Croce et al. (2006) whilst Churchill et al. (2004) made acrylic models 
from the casts of one side of the nasal passages of ten different cadavers.  
In the literature reviewed few of the physical models replicated the full upper airway from the nares to 
the trachea-larynx interface (Mylavarapu et al., 2009, Spence et al., 2012) with most instead 
encompassing only the nasal passageways from the nares to some region of the nasopharynx 
(Churchill et al., 2004, Croce et al., 2006, Doorly et al., 2008a, Hahn et al., 1993, Hörschler et al., 
2006, Janssens et al., 2001, Kim and Chung, 2004, Kook Kim et al., 2006, Schreck et al., 1993). This 
latter case could affect flow patterns observed during expiratory flows as it has been shown that the 
contraction of the velopharynx produces a jet-like flow into the nasopharynx (Jeong et al., 2007, 
Spence et al., 2012, Stringer et al., 2010). Models are sometimes further simplified to include only 
one side of the nasal cavity and no nasopharynx (Hahn et al., 1993, Kelly et al., 2000), the septum 
wall extended into the nasopharynx (Churchill et al., 2004, Kim and Haw, 2004) or the full-width 
nasopharynx (Doorly et al., 2008a, Schreck et al., 1993). Due to the asymmetrical nature of the 
airways these simplifications do not faithfully replicate the conditions and could reasonably alter the 
flow characteristics observed. In particular the unilateral model used by Hahn et al. (1993) was 
truncated just posterior to the nasal septum and the flow-driving fan was mounted in line with the 
nasal cavity via a duct. A consequence of this is that expiratory flow characteristics produced by the 
expansion and change of flow direction which occur through the nasopharynx would not be observed. 
With the exceptions of Croce et al. (2006), Janssens et al. (2001) and Spence et al. (2012) the in vitro 
studies reviewed excluded the geometry of the face surrounding the nares, opting for a flat cross-
section of the naris on an external model face or a tube lofted to the naris. As air is drawn from a 
hemispherical region around the nares the facial geometry may affect the flow profile entering the 
nostrils and should ideally be included (Doorly et al., 2008b). The inclusion of vibrissae was found in 
only the model by Hahn et al. (1993), who concluded their inclusion to have little effect on the flow 
within the main nasal cavity. No in vitro study replicated the natural and variable compliance of the 
airway or the temperature and humidity exchanges which naturally occur within it. 
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In the reviewed CFD studies the airway meshes employed had similar simplifications to the physical 
models with some encompassing the whole upper airway (Jeong et al., 2007, Stringer et al., 2010) and 
others just the nasal passages, with either one side of the nasal cavity included (Gambaruto et al., 
2009, Hörschler et al., 2006, Pantle et al., 2010) or both (Croce et al., 2006, Ishikawa et al., 2006, 
Mylavarapu et al., 2009, Pantle et al., 2010, Wen et al., 2007). As with the in vitro models most 
airways excluded the facial geometry and began at a flat cross-section to the nares or naris, except in 
the cases of the airways employed by Croce et al. (2006), Taylor et al. (2010) and Stringer et al. 
(2010). At the pharyngeal end of the airway models the flow boundary was most often defined as a 
flat cross section of the nasopharynx (Gambaruto et al., 2009, Ishikawa et al., 2006, Pantle et al., 
2010, Tan et al., 2012, Taylor et al., 2010) or the trachea-larynx interface (Mylavarapu et al., 2009) 
though some models included a lofted extension from either the nasopharynx cross section (Croce et 
al., 2006, Hörschler et al., 2006, Wen et al., 2007) or the trachea-larynx interface (Stringer et al., 
2010) to allow for flow profile development. The compliance of the airways and presence of vibrissae 
were excluded in all reviewed CFD studies. The temperature and humidity exchange between the 
airway and the airflow was investigated only by Naftali et al. (1998) in a highly simplified model of 
one side of the nasal cavity.  
3.2 Replication of Respiratory Flows for In Vitro and CFD Studies 
Steady-state flow conditions were most commonly employed for in vitro experiments and CFD 
simulations, with inspiration and expiration flows supplied at one or more constant rates usually in the 
range of those found in vivo during natural breathing. Unsteady flow in vitro experiments performed 
by Naito et al. (1989) employed a live subject to provide the flow by mouth-breathing directly through 
the posterior access to the model nasopharynx. Though this method provides physiologically realistic 
flows accurate repetition would be difficult. A piston pump was used by two further in vitro studies to 
provide the unsteady flow (Janssens et al., 2001, Spence et al., 2012) which, in the case of Spence et 
al. (2012), was driven by a Fourier series derived from in vivo measurements. Unsteady CFD 
simulations were carried out by applying an oscillatory equation derived from in vivo breathing 
measurements (Naftali et al., 1998, Stringer et al., 2010) or a simple sinusoidal wave scaled to 
represent an average adult tidal volume and respiratory rate (Ishikawa et al., 2006). 
An important component of simulating flow using CFD is the definition of boundary conditions and 
inflows and outflows. In the CFD study by Taylor et al. (2010) the influence of the inspiratory 
entrance condition to the nares was investigated and it was found that the form of the surrounding face 
affected the velocity profile entering the nares. This was not accurately replicated by applying a 
uniform velocity profile to the nares cross section, yielding significantly different flow patterns within 
the nasal passages. By extending the entrance to the nares with a convergent pipe and applying a 
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uniform or parabolic velocity profile to the inlet Taylor et al. (2010) obtained flow predictions much 
closer to those found when the face was included. A number of inflow and outflow boundary 
conditions were employed in the reviewed CFD studies including a uniform (Gambaruto et al., 2009, 
Ishikawa et al., 2006) and non-uniform (Hörschler et al., 2006) velocity profile at the nares, constant 
mass flux at the pharynx (Mylavarapu et al., 2009, Tan et al., 2012) and nares (Pantle et al., 2010), 
and, in the case of models which included the facial geometry, a uniform pressure at the pharynx flow 
boundary and a uniform ambient pressure at the open surface of a box surrounding the face (Croce et 
al., 2006, Stringer et al., 2010, Taylor et al., 2010). 
3.3 Studies of Pressure 
In Vivo 
The conducting airways provide a path from the exterior to the lungs with the nasal cavity further 
acting to condition incoming air and recover heat and humidity during air expulsion. This passageway 
provides a resistance to the flow of air resulting in a loss of pressure along the flow path. The 
magnitude of this resistance depends on the form of the airways with the nasal cavity attributing 
approximately one half of the overall resistance during nasal breathing (Swift and Proctor, 1977). In 
most people the nasal mucosa which lines each nasal cavity alternately swell and shrink over a period 
of 3 – 7 hours known as the nasal cycle, causing changes in resistance within each cavity (Baraniuk 
and Kim, 2007, Hasegawa and Kern, 1978). The total resistance across the entire nasal cavity remains 
approximately the same throughout this cycle (Hasegawa and Kern, 1978). Verin et al. (2002) found 
that obstructive sleep apnoea (OSA) sufferers presented higher median upper airway resistance than 
their healthy counterparts whilst in a study of 1,000 rhinological patients by McCaffrey and Kern 
(1979) it was found that perceived nasal obstruction correlated well with increased resistance. While 
some pathologies increase the airway resistance which can lead to a predisposition to airway collapse, 
as is the case for OSA, others cause a reduction in the breathing effort a sufferer can exert as in the 
case of chronic obstructive pulmonary disease (COPD) (Chatila et al., 2004, Verin et al., 2002). 
The fifth mechanism of action of NHF therapy proposed by Dysart et al. (2009) is the creation of PAP 
leading to improved lung recruitment. Mechanical ventilation by CPAP is commonly used as a means 
of providing PAP to increase lung recruitment and reduce the occurrence of apnoeas for patients 
ranging from neonates to adults (Campbell et al., 2006, Saslow et al., 2006, Shoemaker et al., 2007, 
Smith et al., 2003, McKiernan et al., 2010). CPAP therapy generates PAP by administration of 
positive pressure flow to the user via a sealed nasal or full-face mask. As this type of therapy can be 
poorly tolerated due to the restrictive nature of the mask it is sometimes necessary for escalation to 
invasive respiratory support such as intubation (Groves and Tobin, 2007, McKiernan et al., 2010). An 
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alternative non-invasive method of generating PAP without the use of a restrictive mask is provided 
by NHF therapy.  
NHF therapy has become a widely accepted treatment for term and preterm infants (de Klerk, 2008, 
Shoemaker et al., 2007) and has been the focus of much recent research with many in vivo studies 
finding significant levels of PAP generated within the upper airway during use (Kubicka et al., 2008, 
Milési et al., 2013, Spence et al., 2007, Wilkinson et al., 2007). The use of NHF therapy as an 
alternative to CPAP in adults is less common; however, adult in vivo studies have found PAP 
generation by NHF therapy. In a study of 10 healthy adults Groves and Tobin (2007) found increased 
expiratory pharyngeal pressures occurred during NHF therapy with pressure related to the rate of flow 
for both open and closed mouth positions. The closed mouth position produced significantly higher 
pressures while significant differences were also seen as a result patient gender with females 
experiencing greater pressures. A similar study by Ritchie et al. (2011) also measured positive 
pressures in the laryngopharynx with an almost linear relation between NHF flow rate and pressure in 
10 healthy adults during at rest nasal breathing. A positive linear relationship between NHF flow rate 
and pressure within the oropharynx was also reported by Parke et al. (2011a) for both mouth open and 
closed breathing in a study of 15 post-cardiac surgery patients. A recent study by Bräunlich et al. 
(2013) of the effects of NHF therapy on patients suffering from COPD and idiopathic pulmonary 
fibrosis (IPF) found an increase in both mean pressure and pressure amplitude in the nasopharynx 
with the use of NHF when compared to spontaneous breathing.  
Measurements of nasal resistance and pressures in vivo provide useful physiological information but 
are limited in many ways such as accessibility. Rhinometry measurements capture the flow rate and 
pressure difference across the nasal cavity for anterior rhinometry and between the nares and the oral 
cavity for posterior rhinometry, allowing for the determination of resistance over these larger regions. 
Measurements of pressure at more specific positions within the airway are possible through the use of 
catheters, either with micro-transducers mounted within the catheter body or attached to external 
transducer systems (Akkermans, 1991), however use of catheters is invasive and placement 
approximate.  
In Vitro 
In vitro experimental methods provide an alternative to in vivo measurements allowing for greater 
airway access and greater control of the variables such as airway geometry and respiratory rate which 
vary widely across adult populations. In a 3:1 scale of a healthy, adult left nasal passage Schreck et al. 
(1993) measured the pressure drop across three regions; the nasal vestibule, nasal cavity and the 
nasopharynx; during a range of constant inspiratory and expiratory flows. It was found that for flows 
greater than 15 LPM the major contributor to pressure losses was the rapid contraction and expansion 
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at the nasal valve. This is similar to the in vivo findings of Swift and Proctor (1977) who found that 
the largest pressure change occurred within the first 1.5 cm of the nasal cavity for normal subjects. 
Moody plots made from the nasal valve measurements indicated a transition from laminar to turbulent 
flow regime at an approximate flow rate 15 LPM, the same flow rate at which the nasal valve became 
the highest contributor to pressure losses. Further pressure measurements by Schreck et al. (1993) 
showed that reduction of the cross-sectional area of the nasal valve, blocking of the upper and middle 
meatuses and increasing the size of the inferior turbinate all caused increased pressure losses.  
Measurements of the pressure differential across the nasal cavity of a plastinated head at a range of 
constant inspiratory and expiratory flow rates by Croce et al. (2006) were used to derive Moody 
diagrams for the individual left and right sides and the nasal cavity overall. For each of the three 
regions the inspiration and expiration curves aligned inferring resistance and pressure losses within 
the nasal cavity were the same in both flow directions. Naito et al. (1989) investigated the influence of 
18 nasal abnormalities on the resistance of a nasal passage model during natural breathing flows. Of 
the diseases replicated swelling of the inferior turbinate, either at the anterior portion or severe diffuse 
swelling, was found to generate the most significant resistance increase. This was further exacerbated 
when the severe diffuse swelling was simulated in conjunction with other minor abnormalities. 
In vitro measurement of static pressures during a steady expiratory flow were made at 16 positions 
within a twice scale upper airway model in a study by Mylavarapu et al. (2009). Pressure ports were 
located along the length of the posterior pharynx, along the inferior lateral wall of the left nasal cavity, 
and around the perimeter of the velopharynx cross-section. It was stated that a constant peak flow rate 
of 200 LPM was used due to a lack of low-pressure sensing range, however it is not clear whether this 
value is that used in vitro or whether it has been scaled back by half to in vivo levels. In either case 
this flow rate is much higher that the peak flow rates seen in vivo during resting breathing. 
Nevertheless the use of a high concentration of static pressure measurement positions throughout the 
airway illustrated local pressure differences not seen in other in vitro or in vivo studies. A large 
reduction in pressure was observed as the expiratory flow passed from the oropharynx into the 
minimum cross section of the velopharynx followed by a pressure recovery during the expansion into 
the subsequent nasopharynx. A wide variation in static pressure was seen around the velopharynx 
circumference with a highly negative pressure at the anterior wall yet a positive pressure at the left 
wall. Measurements at the four equally-spaced points along the length of the nasal cavity showed an 
almost constant pressure until a large drop occurred at the most anterior point, again agreeing with the 






The use of computational fluid dynamics (CFD) allows for comprehensive mapping of flow 
characteristics within complex geometries and as such has been employed in a number of studies to 
investigate flows in nasal cavities and upper airways. It has been proposed that CFD could be used by 
surgeons to validate modification strategies for correcting nasal pathologies prior to surgery to reduce 
the rate of unsuccessful procedures (Müller-Wittig et al., 2002, Pantle et al., 2010). Although CFD has 
the power to provide large amounts of information such investigations are computationally expensive 
and are in most cases only solved for constant flow conditions. Furthermore experimental replication 
in some part is required for validation of the model and results. In a flow study within a plastinated 
head by Croce et al. (2006) a CFD model of the airway was reconstructed from CT scan images of the 
head used for in vitro measurements. A linear model was used to simulate constant inspiratory flow 
rates of 6.54, 13.86 and 21.18 LPM. Mean total pressures within each side of the nasal cavity were 
extracted at numerous cross sections along its length from which it was determined that 48% of the 
total pressure losses occurred in the region of the nasal valve and 76% occurred before the beginning 
of the turbinates, agreeing well with the findings of Schreck et al. (1993). Similarly, Wen et al. (2007) 
found the greatest resistance to pressure occurred in the first 1.5 – 2.5 cm from the nasal inlet when 
simulating steady-state flows through a nasal cavity using a Reynolds-averaged Navier-Stokes based 
k-ω turbulent model. A study by Hörschler et al. (2006) investigated the impact of the inferior and 
middle turbinates on pressure losses through the nasal cavity by simulating constant flows through 
simplified and modified nasal passages. Through this they found that the presence of the lower 
turbinate had the greatest impact on the pressure losses through the nasal cavity. An evaluation of 
CFD modelling methods during steady state flows through an upper airway was carried out by 
Mylavarapu et al. (2009) and compared to experimentally determined pressures from which it was 
concluded that use of the standard k-ω model produced the most similar results.  
3.4 Studies of Flow Patterns and Turbulence 
In Vitro 
Many in vitro experiments and CFD studies have been dedicated to determining the airflow patterns 
within the upper airways. Flow visualisation methods using tracer fluids have been used for decades 
to observe the flow patterns within the nasal passage and upper airway (Churchill et al., 2004, Doorly 
et al., 2008a, Müller-Wittig et al., 2002, Proetz, 1953). A study by Churchill et al. (2004) which used 
constant flows of water and tracer dyes to visualise the flows through ten acrylic adult nasal passage 
models found that not only did the flow regime vary significantly across the sample group, so too did 
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the path of major flow. No model exhibited truly laminar flow for any of the flow rates tested, with 
three models showing fully turbulent flow at the lowest in vivo flow rate (1.5 LPM), and two models 
persisting with transitional flow through to the highest in vivo flow rates (39 and 42 LPM). In a recent 
study by Doorly et al. (2008a) a number of recirculating flows were identified within a twice scale 
nasal cavity model with the use of dye visualisation and particle image velocimetry (PIV). PIV 
employs short exposure cameras to capture the movement of light-reflecting particles usually within a 
plane of the flow domain illuminated by a sheet of laser light. The movement of the particles between 
consecutive frames can be resolved by correlation techniques to provide both qualitative and 
quantitative flow data (Chung and Kim, 2008). This is performed computationally in the case of 
digital PIV (DPIV). In more recent years PIV has been employed to experimentally determine the 
flow patterns and velocities within realistic and idealised nasal and upper airway geometries (Doorly 
et al., 2008a, Hopkins et al., 2000, Kelly et al., 2000, Kim and Chung, 2004, Kim and Haw, 2004, 
Kook Kim et al., 2006, Spence et al., 2012, Versteeg and Hargrave, 2001).  
Most PIV studies of nasal airway flows to date have employed steady state flows within the range of 
flow rates seen in vivo during at rest breathing. A number of these studies observed the occurrence of 
a recirculation zone at the anterior nasal cavity during inspiration, superior to the nasal valve (Doorly 
et al., 2008a, Hopkins et al., 2000, Hörschler et al., 2006, Kelly et al., 2000). Doorly et al. (2008a) 
reported the presence of further recirculation zones in the anterior of the middle meatus and at the 
posterior of the olfactory zone during inspiration. PIV measurements during expiration by Hörschler 
et al. (2006) displayed a jet-like flow projecting onto the roof of the nasopharynx from the pharynx 
and being directed toward the superior meatus, whilst during inspiration flow was said to be 
concentrated toward the middle meatus. Inspiratory acceleration through the nasal valve was observed 
in studies by both Doorly et al. (2008a) and Kelly et al. (2000). From their results Hörschler et al. 
(2006) and Kelly et al. (2000) suggested that the flow within the nasal airway was laminar. 
A transient PIV study which employed a realistic at rest breathing pattern was undertaken by Spence 
et al. (2012) using a 1.55 scale model of the control airway employed for the current research 
identified as airway 06B. During the inspiratory phase a region of flow stagnation was seen in the 
anterior nasal cavity above the nasal valve, however the recirculating flow described in other steady 
state experiments (Doorly et al., 2008a, Hopkins et al., 2000, Hörschler et al., 2006, Kelly et al., 2000) 
was not present in this area. During peak expiration a jet-like flow from the pharynx was directed 
toward the roof of the nasopharynx and below this a vortex developed as the flow separated from the 
anterior pharynx wall as it curved forward to form the floor of the nasal cavity. During both expiration 
and inspiration the flow was seen to be concentrated to the middle airway with low flow in the 
olfactory zone and meatuses. Differences in the flow pattern were seen at similar instantaneous flow 
rates during the increase to and decrease from peak expiration, inferring that a quasi-steady 
assumption is inaccurate to describe the flow. Within the same study Spence et al. (2012) also 
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investigated the influence of Optiflow™ NHF therapy at a flow rate of 30 LPM on the upper airway 
flows during transient breathing. High velocities were observed at the nasal valve during expiration as 
the jet from the cannula entered the nasal cavity and was turned back on itself to exit through the 
nares with the expiratory flow from the lungs. Recirculation zones were mapped within the anterior 
nasal cavity both above and below the nasal cannula jet during this expiratory flow. As with the 
natural breathing condition expiratory flow from the pharynx was directed toward the nasopharynx 
roof; however, no vortex was seen below this. During inspiration the vortex in the anterior nasal 
cavity above the cannula jet persisted while the lower vortex had all but disappeared. The jet of flow 
exiting the cannula was directed toward the roof of the nasal cavity during inspiration and was the site 
of maximum velocity during both inspiration, 16.5 m/s, and expiration, 13.6 m/s. Contrary to the 
findings during natural breathing, the quasi-steady flow assumption was deemed applicable to the 
flows observed during the application of 30 LPM NHF therapy. 
Velocity and turbulence profiles within a 20-times scale human nasal cavity at steady inspiratory and 
expiratory flow rates were investigated using hot wire anemometry during research by Hahn et al. 
(1993). Measurements were taken along 85 lateral-medial traverse lines distributed vertically within 
six coronal sections of the nasal cavity spanning the naris to the nasopharynx, allowing for velocity 
and turbulence mapping within the six sections. During an in vivo inspiratory flow rate of 10.8 LPM, 
representing an average breathing flow rate, flow was found to be most highly distributed within the 
lower and middle passages of the nasal cavity. Vibrissae were simulated in the nasal vestibule for 
some measurements and though it was found their presence did slightly increase inspiratory 
turbulence intensity near the nasal valve from 2.5% to 2.9% it had little effect on the downstream 
velocity profile. Turbulence intensities within the nasal cavity at natural inspiratory flows were found 
to be low with a maximum of 3.4% found at the superior entrance to the nasopharynx. Turbulence 
intensities for natural expiratory flows were not given. Hahn et al. (1993) described the flow regime 
during natural breathing flows to be disturbed laminar due to the presence of low turbulence 
intensities throughout the nasal cavity. 
CFD 
The complex flow patterns within the upper airway have been mapped with the use of CFD in a 
number of studies, most of which employ steady state conditions (Croce et al., 2006, Hörschler et al., 
2006, Jeong et al., 2007, Stringer et al., 2010, Wen et al., 2007, Tan et al., 2012) and focus on the 
region spanning the nares to the nasopharynx (Croce et al., 2006, Hörschler et al., 2006, Ishikawa et 
al., 2006, Wen et al., 2007). The presence of a vortex above the nasal valve in a sagittal section of the 
anterior nasal cavity was reported in one or both sides by Croce et al. (2006), Hörschler et al. (2006), 
(Tan et al., 2012) and Wen et al. (2007) during steady inspiration whilst simulations by Stringer et al. 
(2010) found no vortices in this region in either side for similar steady-state conditions. This agrees 
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with the findings of PIV studies described in the previous section which have also shown the presence 
and absence of recirculation in this zone for different airway geometries during steady inspiratory 
flows. Further vortices were found in cross sections of the nasal valve (Wen et al., 2007) and within 
the anterior nasal cavity below the nasal valve (Croce et al., 2006) during steady inspiration. The path 
of mean inspiratory flow varied among studies though consistently low flows were seen in the 
superior region (Croce et al., 2006, Hörschler et al., 2006, Stringer et al., 2010, Wen et al., 2007). 
Simulations within the full upper airway region by Jeong et al. (2007) described the presence of a 
turbulent jet within the pharynx during steady state inspiration with high shear stresses acting upon 
the walls of the velopharynx increasing the chance of airway collapse. Stringer et al. (2010) also 
investigated flows within the pharynx and found the highest turbulent kinetic energy to be 
concentrated within the velopharynx and nasopharynx during the expiration phase. Further steady 
state simulations were performed by Stringer et al. (2010) with the inclusion of an Optiflow™ nasal 
cannula delivering 30 LPM NHF therapy at peak inspiration and expiration. From these simulations 
high velocities were seen in the region of the nasal valve and through the middle and superior airways 
while high vorticities were found in the anterior nasal cavity and near the anterior velopharynx. 
During expiration the cannula jet was observed to turn back on itself forming a clockwise vortex on 
the floor of the anterior nasal cavity. A transient analysis of the nasal passage flows performed by 
Ishikawa et al. (2006) found highest vorticities in the anterior nasal cavity and the posterior nasal 
cavity near the middle turbinate during peak inspiration whilst during peak expiration the former 
remained but the latter changed to near the posterior septum wall. Ishikawa et al. (2006) described the 
flow as laminar as the vortices were time-dependant but not random. 
3.5 Studies of NHF Therapy and Carbon Dioxide Washout 
A number of clinical studies have been undertaken to measure the rate of success of NHF therapy for 
respiratory support in comparison to more conventional non-invasive treatments such as low-flow 
nasal cannula (LFNC), high-flow face mask (HFFM) and CPAP. In these trials blood oxygen 
saturation and rate of intubation or reintubation are often used to measure therapy success, alongside 
other factors such as respiratory rate and therapy tolerance. A randomized trial of the use of NHF 
therapy for post-extubation preterm infants by Campbell et al. (2006) found that it was less effective 
than conventional CPAP therapy and resulted in a higher rate of reintubation and higher O2 
consumption; however, a retrospective study conducted by Shoemaker et al. (2007) of preterm infants 
who received either NHF therapy or CPAP within 96 hours of birth found that patients who received 
NHF therapy required fewer ventilator days whilst CPAP failure was more likely to result in 
intubation. In adult populations NHF therapy is more commonly used as a substitute for LFNC and 
HFFM therapies (Ward, 2013). Tiruvoipati et al. (2010) conducted a randomised cross-over trial to 
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compare the outcomes of HFFM and NHF therapy on 50 post-extubation adults and found that both 
provided a similar level of support with no significant differences in blood oxygenation, blood 
pressure, heart rate, or respiratory rate; however NHF therapy was found to be better tolerated by the 
patients. Two further studies compared ICU patients treated with NHF therapy to those treated with 
HFFM. A prospective open study by Nicolet et al. (2011) allocated 40 post-operative cardiac patients 
either to NHF therapy or HFFM mask based on equipment availability and determined no significant 
differences in the rates of hypoxemia or re-intubation but did find higher tolerance of NHF therapy. A 
more structured study by Parke et al. (2011b) assigned 60 ICU patients to either NHF therapy or 
HFFM in a randomised controlled trial and monitored their blood oxygenation and rate of escalation 
to non-invasive ventilation (NIV), concluding that NHF therapy success was significantly greater than 
HFFM with NHF patients having fewer blood oxygen desaturations and a lower rate of escalation to 
NIV. Chatila et al. (2004) investigated the effectiveness of NHF at providing support to COPD 
patients during rest and exercise in comparison to mouth-delivered low flow oxygen in a cross-over 
trial and found NHF enabled greater exercise time and increased blood oxygenation. Other studies 
have found that the use of NHF was able to increase the blood oxygenation in comparison to 
spontaneous breathing in ICU patients (Sztrymf et al., 2011) and patients suffering from severe acute 
respiratory infection (Rello et al., 2012). A further study by Bräunlich et al. (2013) measured reduced 
CO2 partial pressures in the capillary blood of patients suffering from IPF and COPD during the use 
of NHF therapy inferring it provided a CO2 washout effect.  
The in vivo measurements have provided evidence of the effectiveness of NHF therapy in increasing 
blood oxygenation in a manner similar to or greater than currently used non-invasive therapies, 
supporting its use for those suffering mild to moderate respiratory distress. However, the occurrence 
of CO2 washout cannot be confirmed from the blood gas measurements alone. The PIV mapping by 
Spence et al. (2012) of upper airway flows during transient breathing with NHF therapy implied some 
level of washout occurred due to a continuous flow of air exiting the nasal valves below the cannula 
jet during the entire breath cycle. To the knowledge of the author no studies of the CO2 or O2 
concentrations within the conducting airways during breathing with NHF therapy have been 
conducted to date. Therefore it is the major objective of this research to measure these concentrations 
during transient breathing with and without the presence of NHF therapy to determine whether CO2 
dead space washout occurs and to what extent it is affected by therapy flow rate and airway geometry. 
3.6 Conclusions 
Though in vivo measurements of pressures within the upper airways have been performed at point 
locations, accessibility difficulties prohibit detailed pressure mapping throughout the region or 
measurement of other elements of interest such as flow velocities, turbulence and gas concentrations. 
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Simulations by CFD can be performed to determine flow characteristics which cannot be measured in 
vivo; however, these simulations are computationally expensive and as such are often restricted to 
steady state analysis and, furthermore, require some manner of experimental replication for validation. 
In vitro experiments within replica respiratory systems however provide a means of performing 
invasive measurements while maintaining close control of the system variables. It is for these reasons 
that the investigations carried out within this research were, in all but one case, performed in vitro.  
Anatomically accurate airway models for in vitro experiments can be constructed using CT scan data 
providing scan resolution is high and the airway surface is correctly extracted. Models of airway 
geometry frequently contain only the complex anatomy of the nasal passage, omitting the significant 
features within the pharynx and often retaining only one side of the nasal cavity. In this research 
airway models containing the full upper airway from the face surrounding the nose to the trachea-
larynx interface were 3D-printed from high resolution CT scan data so that all significant anatomical 
features were retained.  
A large number of previous in vitro and CFD studies employed steady state flows when investigating 
flow characteristics within the airways. However, it has been suggested that the transient flows within 
the upper airway cannot be assumed quasi-steady. Thus to properly replicate the transient and 
oscillatory nature of the human breathing pattern, in all in vitro experiments within this research 
transient flows based on in vivo measurements are employed. 
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4 Airway Model Development 
The airway models employed throughout this research to conduct the experimental testing were 1:1 
scale replicas of human airways reproduced from CT scan data of various adults. A total of five 
different adult airway CT scans were developed into models, one of which was made three times via 
two different manufacturing methods. The first six models were developed in 2011 as a part of 
research carried out for a University of Canterbury Mechanical Engineering Final Year Project 
sponsored by FPH. These six included two models made from the same airway CT scan data, referred 
to as airway 06B. A second model,  airway 06B
2
, was produced from this airway after issues were 
found in the method of introducing pressure taps into the initial model, airway 06B
1
, making it 
unusable for static pressure measurements though still useful for other experiments. The seventh 
model, a reproduction via a different printing method of the second airway 06B model with reduced 
material, was manufactured during the course of this research giving a total of three models from the 
airway 06B data. All models were manufactured using 3D printing methods. Table 1 lists the seven 
different airway models used over the course of this research, the names by which they will be 
referred to in this thesis and certain other important details pertaining to each. 
Table 1: Details of the upper airway models used for this research. 
4.1 Digital Airway Preparation 
The first step to preparing the models for printing was to extract the airway surface from CT scan 
data. A CT scan takes multiple sequential two-dimensional images of the body density at each image 
Airway N
o 
Reference Name Age Gender Printing Method Material Volume [ml] 
06B Airway 06B
1




 Airway 06B Jetted Photopolymer Acrylic 
07B Airway 07B 43 M FDM ABS 60.16 
09 Airway 09 41 F FDM ABS 48.27 
10 Airway 10 51 M FDM ABS 57.57 
16 Airway 16 17 M FDM ABS 43.70 
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slice across the scan volume. The colour of each pixel, ranging in greyscale from black to white, 
denotes the density measured at the pixel position. Together, the collection of image slices forms a 
three-dimensional density map. Each of the five airway CT scan datasets chosen had an image slice 
separation of 0.6 mm, thus preserving a large amount of airway detail. To extract the airway surface 
from these images the process of segmentation was used. Segmentation is an operation which 
separates pixels into two groups either side of a nominated pixel density value, known as the 
threshold. The interface of these two sets of pixels is then extracted as a surface. The selection of the 
threshold value used to extract each airway was made by trial and error iterating the process until the 
surface extracted was as complete and correct as possible, when compared to the known upper airway 
anatomy, without omitting any significant features.  
Before the airway surface was edited and developed into a physical model it was first scrutinised to 
ensure it met a number of important criteria. One of the criteria imposed was that the airway should be 
healthy and representative of the general population, free of any geometric defects which may 
adversely affect experimental results. A consequence of this is that most scans which contain the full 
upper airway are not likely usable as they are taken with the express purpose of mapping the airway to 
detect irregularities. As there are health risks associated with excess exposure to the CT scanning 
process, it is uncommon for the entire upper airway to be captured in scans taken of other anatomical 
features within the same area. These two factors made acquisition of appropriate scan data a difficult 
task and thus the first check of segmented airways was to ensure all relevant geometric features, from 
the nares to the top of the trachea, were present and not truncated during the scanning process. A total 
of five airways of the twelve unique available scans met these criteria. 
It was necessary then to edit each extracted airway surface to remove certain extraneous features such 
as the paranasal sinuses, auditory tubes and the tear ducts (Tortora and Derrickson, 2006). As the 
sinuses and the auditory tubes are air reservoirs which are only open to the exterior via small ostium 
into the upper airway, they do not experience significant air movement but rather pressure 
equalisation. Although the tear ducts are open to the exterior at both ends, the opening of the tear 
ducts into the nasal cavity is protected by a thin mucous membrane, Hasner's membrane, which helps 
to prevent flow back into the duct (Müller et al., 1978). These features therefore do not participate in 
the flow of air through the upper airway during breathing and were removed to reduce the model size 
and allow greater access to the airway. Each feature was removed as close to the airway volume as 
possible, where the diameters of the connecting orifices were at minimum. The small holes which 
remained in the airway surface meshes were capped with domes to provide a smooth continuous 
surface which would not adversely affect the flow pattern.  
Further editing was required to crop each surface so that only the upper airway and some of the facial 
geometry was present. A small region of the face around the nose was retained as during inhalation air 
is drawn from a hemispherical region around the nares, the flow profile within which may be affected 
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by the surrounding geometry (Doorly et al., 2008b). Additionally, a certain amount of the facial 
geometry below the nares had to be retained to allow the nasal cannulae to be properly fitted to the 
final models. The inferior portion of the airway surface was truncated so that the passage terminated 
at the transition from larynx to trachea. Each mesh was therefore an open surface encompassing only 
the complex upper airway and a portion of the face. The open mesh of the first upper airway, airway 
06B, is shown in Figure 7. 
Figure 7: Open mesh of upper airway 06B. 
Before these meshes could be materialised into physical models, the open surfaces had to be closed to 
provide a three dimensional volume. This took the form of an irregular box fitted to the shape of the 
airway, with the facial features forming one face and the inferior outlet of the upper airway exiting on 
another. The airway formed a cavity through the box which could be manufactured by 3D printing. As 
the trachea was to be represented in the experimental system as a circular tube with a 15 mm 
diameter, a smooth transition from the larynx-trachea cross section of the airway mesh was 
accomplished by forming a lofted surface to a 15 mm diameter orifice on the base of the box.  
Because the airways were to be 3D printed it was deemed necessary to make each so the majority of 
the airway could be easily accessed for inspection and removal of any remaining support material 
deposited during printing. This lead to the sectioning of each airway model into three parts, a left and 
right side plus a small central piece containing the nasal septum. An example of these is shown in the 
form of airway 06B
2
 in Figure 8. 
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Figure 8: Three pieces of the airway 06B
2
 model. 
Prior to manufacture, each airway model mesh was prepared for the measurement of static pressures 
in various locations by the introduction of pilot holes for pressure taps. In the case of the first airway 
06B
1
 model pressure taps were drilled post manufacture without the use of pilot holes and, on 
inspection, it was found that a number of the taps did not enter the model normal to the airway 
surface. This introduced error to the static pressure measurements from dynamic pressure effects. 
Establishing pilot holes for the pressure taps in the model mesh allowed for accurate placement, 
ensuring each tap entered the correct anatomical region perpendicular to the airway surface. Five to 
six bolt holes for locating and securing the model pieces together were also introduced to each airway 
model at this stage.  
Some of the later models to be manufactured underwent a final editing process before printing. As 
large portion of the production costs is for the print material, reduction of material volume was 
valuable. It was possible to achieve this by performing a shelling operation in which the solid volume 
was reduced to a shell with a minimum wall thickness of 3 mm. In the case of the airway 06B model 
further editing was carried out to remove as much of the non-functional material as possible. This left 
the airway surface, the lower face of the original box and circular bosses for the bolt and pressure tap 
holes. A comparison of this airway 06B model version to the earlier airway 06B
2
 version is given in 
Figure 9 to show the volume reduction. 
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Figure 9: Reduced material airway 06B model compared to the earlier airway 06B
2
 model. 
4.2 Model Manufacture 
The initial six airway models made in 2011 were manufactured using the fused deposition modelling 
(FDM) process. This produced models in ABS plastic by depositing heated layers of the plastic 
filament in 0.254 mm thicknesses. These models are highly cost effective but due to the method of 
manufacture are prone to a small level of porosity. This issue was addressed during model clean up. 
The duplicate airway 06B model was manufactured during the course of this research by the more 
refined process of jetted photopolymer printing, using the Projet HD 3000 Plus by 3D Systems. This 
produced non-porous model pieces out of an acrylic photopolymer, Visijet EX200, with a layer 
thickness of only 29 μm.  
A few post-manufacture clean up and preparation tasks were required to make the models ready for 
experimental use. Support material deposited during the 3D printing process was removed. Pressure 
tap holes placed in the model before printing were drilled out to size with a hand drill. As previously 
remarked the FDM models suffered from a small level of porosity due to the manufacture method. To 
mitigate this issue the inner surfaces of the FDM models were sealed with multiple coatings of diluted 
PVA glue. As PVA is water soluble, this method of sealing allowed for future removal if desired. The 
sealing of the inner surface also provided a second benefit by smoothing the transitions between the 
layers of the model, reducing the surface roughness. During the process of support material removal; 
using hot water, detergent, sonication and scraping; the central piece of the acrylic airway 06B model 
became slightly bowed such that when assembled the model had a not insignificant gap between the 
central and right pieces. The warped central piece was straightened by reheating it in a bath of hot 
water just below the melting temperature of 65°C then bending it carefully back into shape so that it 
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lay level on a flat surface. Great care was taken to ensure the rest of the piece was undamaged during 
this process. Figure 10 shows the three pieces of the airway 06B model duplicate prior to assembly. 
Figure 10: Three pieces of airway 06B model prior to assembly. 
Assembly of the models required a sealant between the pieces to prevent leaks. Universal Blue™, a 
non-setting gasket sealant made by Hylomar™, was used for this purpose as it provided a seal without 
permanently binding the pieces together. A thin layer of Universal Blue was spread across all 
contacting surfaces of each model pieces before assembly. The pieces were then assembled with firm 
finger pressure and fastened together with bolts to provide a tight fit with no movement between the 
pieces. As the Universal Blue is a non-setting sealant tightening of the bolts caused excess product to 
move to the edges of the pieces. To mitigate this each model was unfastened and opened so all excess 
product which had migrated into the airway could be removed. Models were then reassembled and 




5 Experimental Respiratory System 
Throughout the course of this research an experimental respiratory system designed to replicate that 
of an average human adult was developed and evolved for use in the in vitro experiments. This 
research was performed in vitro as it allowed for improved accessibility along with much greater 
control of respiratory parameters for the variety of measurements desired when compared to the much 
less accessible and varied nature of in vivo experiments. To gain meaningful information from this 
research it was then important to develop a system which faithfully replicated an average human 
respiratory system with which the experiments could be conducted. The experimental respiratory 
system which was developed and utilised took a number of different forms over the course of the 
research dependent on what measurements were being conducted, however the major components 
consistent throughout all variations were the pump, airway models and the Optiflow™ cannula 
system. This chapter described in detail all versions of the experimental respiratory system employed. 
5.1 Permanent System Components 
This section details the experimental system components which were employed in all of the 
experiments performed and described within this thesis.  
5.1.1 Airway Models 
As described in the previous chapter, seven different airway models derived from five unique airway 
geometries were used during the course of this research. Three of these airway models were slightly 
different versions of the same model, all containing the same airway geometry of airway 06B. This 
airway 06B geometry was chosen as the benchmark airway for all in vitro experiments, each 
employing one of the three duplicate models as stated in the method. The other four airway models 
were used only in experiments where the effect of airway geometry on turbulence intensity and 
Optiflow™ NHF therapy efficacy were investigated. All models had 21 equivalent pressure tap holes 
entering the airway from the outer surface of the model through which the pressure taps required for 
static pressure measurement could be inserted. These holes were kept to a minimum (1.7 mm 
diameter) and entered the airway perpendicular to its surface to prevent flow disturbance. When not in 




Figure 11: Comparison of the new acrylic airway 06B model (left) to the older style airway 06B
2
 model 
made of ABS plastic (right). 
All but one of the airway models was manufactured in ABS plastic via 3D printing during previous 
research, with the most recent model printed in acrylic during these studies. An example of each type 
of model is given in the photo of Figure 11. The inferior face of the models was a flat surface 
containing a 15 mm diameter hole, lofted to the airway as described in Chapter 4. Aluminium 
connections, also produced in the previous research, provided a method of attaching a flow delivery 
passageway to the airway model. These connections, with a 15 mm diameter hole on one face to 
match that on the model, could be secured to the airway models either by bolts or with a thin layer of 
silicone glue. When bolted, a thin layer of Universal Blue gasket glue was used to provide a seal 
whilst the use of silicone glue alone both fixed the connection to the airway and provided a seal. A 
dowel was used to align the two holes when fixing the aluminium connection to the airway models. 
At the opposing end of the aluminium connection was a tapped hole into which a 15 mm inner 
diameter brass tube with a 1/2 inch BSP F external thread could be fastened. This provided a smooth, 
straight entrance for flow from the pipe to enter into the airway model. 
5.1.2 Lung Pump 
A piston pump, inherited from previous research within the same field and illustrated by Figure 12, 
was used to replicate the action of an average pair of human lungs by providing the transient 
oscillatory flows of breathing. An acrylic tube with a nominal diameter of 140 mm comprised the 
pump cylinder with an acrylic piston head sealed by two back-to-back nitrile lip seals. A Hirwin 
precision rolled ball screw and ball nut with a 5 mm pitch provided the linear piston motion from an 
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Astrosyn L259RE stepper motor driven by an Astrosyn P808A stepper motor driver. A fixed block 
style support and SBC flange supported the ball screw while a Rollon compact 18 series rail with a T 
slider supported the piston rod. A National Instruments 9401 digital module and a 9172 compact 
DAQ chassis allowed the stepper motor to be controlled by a Labview program which took a five 
coefficient Fourier series input to replicate the oscillatory flow of breathing.  
Figure 12: Illustration of the piston pump employed to replicate the action of the lungs. 
The volume contained within the pump could be altered by shifting the home position of the piston 
and was controlled so that during CO2 washout measurement it contained the same volume as the 
FRC of an average adult. In its original form the outlet of the pump consisted of a cone and numerous 
industrial connections necking it down from the pump diameter to 20 mm, similar to an approximate 
trachea diameter of 25 mm (Tortora and Derrickson, 2006). This large number of connections, shown 
in Figure 13, contained a large volume which was initially assigned as a portion of the lung FRC in 
the early CO2 decay measurements of Experimental Method Version One. However a measure of the 
system's fidelity was carried out which proved that this system, although adequate for testing pressure 
and turbulence within the upper airway, was not accurately replicating the cycle of gas concentrations 
observed at the nares of a live subject. As a result of this the design of the pump was changed so that 
at its outlet was a flat acrylic plate with a single, circular orifice to which the components making up 
the anatomic dead space, including the gas sensing elements and the upper airway models, could be 
directly attached. This new pump design is illustrated in Figure 14. With this new exit condition it was 
possible to contain the entire FRC, taken to be the average adult value of 2.4 litres, within the lung 
pump and the anatomic dead space without. By making these adjustments to the pump the gas 
concentration cycle issues were rectified so that the system closely replicated the CO2 concentration 
cycle of a live subject.  
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Figure 13: Large number of connections at the original pump exit. 
 
Figure 14: Illustration of piston pump with improved flat plate exit. 
5.1.3 Optiflow™ Nasal High Flow System 
Throughout all experiments in which NHF therapy was applied to the airway models FPH Optiflow™ 
cannulae were used with one exception, in the case of the final CO2 washout experiment detailed in 
Chapter 9 where a flared prong cannula was employed. Large size cannulae were employed for all 
experiments bar those in which cannula size and prong penetration depth dependencies of CO2 
washout were examined. Air at room temperature from a reticulated compressed airline was used to 
supply the cannulae with the high flows. For each experiment air from the airline was directed 
through a Norgren pressure regulator, Platon NG series rotameter and a FPH breathing circuit filter 
before entering a standard FPH RT-series breathing circuit and finally into an Optiflow™ cannula. 
The level of NHF required was set at the rotameter by supply adjustment at the pressure regulator. 
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All of the three Optiflow™ cannula sizes available were used for some experiments during the course 
of this research. When fitting the cannulae on the model a standard process was always undertaken. 
The cannula was rested in the space below the nostrils and above the upper lip of the model. The 
prongs were adjusted so that they protruded into the nostrils at their natural angle. The cannula elastic 
strap was then strung around the model and pulled tight so that the cannula was held fast but not 
strained from its natural resting position. Finally the cannula positioning was checked and adjusted so 
that it was sitting centrally between the two nares.  
When NHF therapy was administered to the airway models during experiments, a range of 
measurements were taken to encompass NHF flow rates from 10 to 60 LPM at discreet intervals of 10 
LPM. This range is of particular interest as it is the range of Optiflow™ NHF therapy flow rates 
which are currently used by clinicians. As the air supplied to the Optiflow™ cannula for 
experimentation was sourced from a reticulated airline, airline pressure was sometimes low and flows 
greater than 60 LPM were unattainable. However, whenever flows greater than 60 LPM were possible 
during testing experiments were conducted to the highest possible flow rate at the same 10 LPM 
increments.  
5.2 Static Pressure Measurement Specific Components 
The system components described in this section are specific to the static pressure experiments 
undertaken as described in Chapter 7, and together with the permanent system components make up 
the full experimental system employed. 
Pump to Airway Model Intermediary Connections 
For measurements of upper airway pressures during natural breathing and breathing with NHF 
therapy flows it was desirable to condition the velocity profile of the flow from the pump. The profile 
of the flow exiting the lungs during expiration in live subjects was not known and, for the purpose of 
determining the pressures within the upper airway, it was not considered necessary to replicate it as 
the effects of the tortuous geometry would rapidly dominate. On inspiration, the flow profile is 
determined by the facial geometry surrounding the nares, which is faithfully replicated in the models. 
The upper airway is a complex geometrical structure linked to the lungs via the trachea, an 
approximately straight, circular passageway of approximately 25 mm in diameter and 120 mm in 
length (Tortora and Derrickson, 2006). The airway models used for experimentation were all made 
such that they began at the transition from the larynx to the trachea, that is, at the superior extremity 
of the trachea. Because of these factors it was assumed that a straight entrance to the upper airway 
would provide a flow from which the pressure characteristics within the upper airway could be 
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determined. To achieve this, a 550 mm (36 diameters) length of 15 mm inner diameter brass pipe was 
installed at the inferior entrance to the airway model via the aluminium connector previously 
described. The opposing end of the pipe was then connected to a TSI 4040 thermal anemometer 
flowmeter via a flexible tube fitting with an inner diameter of approximately 20 mm. The connection 
between the flowmeter and the pump was made by another short length of the same flexible tubing. 
The airway model was elevated on an angled platform so that all pressure tap positions could be 
accessed for measurement. An illustration of this system is given in Figure 15. 
Figure 15: Schematic of the experimental system used for static pressure measurements. 
Pressure Sensing Elements 
A 32-port pressure transducing system, previously developed for static pressure measurements within 
these same airway models during constant flows, was employed for measuring the static airway 
pressures during oscillatory breathing flows. 32 Honeywell S&C differential pressure transducers 
with a sensing range of -2500 to 2500 Pa and a 0.1 Pa resolution were used within the system. 
Connecting the pressure sensors to measurement points in the airway models were lengths of silicone 
tubing with short sections of hypodermic tube at the open end. Each of these hypodermic tubes was 
inserted into a pressure tap hole within the airway model so that they terminated no further than 5 mm 
from the inner surface of the airway. The gap between each pressure tap hole and the hypodermic tube 




5.3 Turbulence Intensity Measurement Specific Components  
The system components described in this section are specific to the turbulence intensity experiments 
undertaken as described in Chapter 8, and together with the permanent system components make up 
the full experimental system employed. 
Pump to Airway Model Intermediary Connections 
The components connecting the pump to the airway for turbulence measurements were the same as 
described for use in the static pressure measurements. The reasons for this are very similar to those 
above, with the velocity and turbulence attributes of the flow due to the geometry of the upper airway 
being of the greatest interest, and the turbulence of the flows exiting the lungs being unknown. The 
airway model was again supported on an elevated frame to allow access to the velopharynx for 
turbulence testing along an anterior to posterior traverse. A traverse slide with a clamp to hold the hot 
wire probe support was mounted to the frame at a right angle to the lay of the airway model, as shown 
in Figure 16. The traverse slide had a scale accuracy of 0.05 mm for accurate positioning of the hot 
wire probe within the velopharynx of the airway model. Both the positioning of the airway model and 
the traverse slide on the frame could be manually adjusted relative to one another to align the probe 
with the entrance hole into the model's velopharynx. 
Flow Velocity and Turbulence Sensing Elements  
A hot wire anemometry system was used for measuring the transient flow velocities and turbulence 
intensities within the velopharynx and at the external nares of an upper airway model. Three older hot 
wire systems; a DISA, a TSI and a third system previously developed in house; were initially trialled 
for use but all proved to be unstable. A new all-in-one system, the Dantec Dynamics multi-channel 
constant temperature anemometer (CTA) with hot wire calibrator and software, was purchased for 
these measurements. A Dantec Dynamics 55P11 straight miniature wire probe mounted in a 55H21 
long straight probe support and connected to the multi-channel CTA with a 4 m coaxial cable was 
used for all measurements. Data from the probe was captured using the system software. 
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Figure 16: Traverse slide with probe support. 
5.4 Carbon Dioxide Washout Measurement Specific Components 
Over the course of this research two methods of determining the efficacy of anatomic dead space 
washout with the use of Optiflow™ NHF therapy were carried out. The first method implemented 
Experimental Method Version One, measured the decay of CO2 concentration at a single 
measurement point. This was carried out by initially adding a known volume of CO2 to the pump 
while at rest then beginning the breathing cycle and logging the concentration as it decayed. This 
method was not physiologically representative of the respiratory process but aimed to gain relative 
information on the efficacy of NHF therapy. The second method, Experimental Method Version Two, 
aimed to replicate the continuous process of respiration and determine an average concentration of 
CO2 at a single point. This was achieved by measuring the CO2 concentration over many breathing 
cycles while replicating CO2 production in the lungs with a steady flow of CO2 into the pump, in 
order to gain a temporal average of the CO2 concentration. Certain components of the system varied 
between each of these two methods, however the same method of introducing the CO2 to the pump 
was employed for both. All are described below and, where the system components were unique to a 
method, they are denoted as Version One or Two for first and second methods respectively.  
5.4.1 Carbon Dioxide Feed 
A 6 mm diameter inlet into the top of the pump cylinder, positioned near the pump outlet and gated by 
a manual ball valve, allowed an entry point for the introduction of CO2. Through this inlet a small 
bleed of CO2 could be fed into the lung volume for CO2 washout measurements, doping the air within 
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to a known concentration and thus replicating the diffusion of CO2 into the lung which occurs during 
pulmonary respiration. The CO2 gas of purity greater than 99.8% was supplied from a compressed gas 
cylinder. Before entering the pump volume the CO2 passed through a Norgren pressure gauge 
following which the flow rate was metered to the desired level via a King Instruments 7430 series low 
flow rotameter. Because the rotameter was not new a check on its calibration was carried out. The 
rotameter was connected to a low flow rate air supply at its inlet and its outlet was fed into a TSI 4140 
low flow thermal anemometer flow meter by a short length of tube, to prevent significant pressure 
losses. Readings on both meters were taken for comparison at 10 ml/min intervals over the 0 to 100 
ml/min range of the rotameter. Analysis of the readings from the two different flow meters showed 
that the rotameter was reading high at all points. The relation between the two flow meters, however, 
had a strong linear trend which could be used to correct for the rotameter's calibration error.  
As the rotameter was made to meter flows of air, a conversion factor had to be applied to the desired 
flow rate of CO2 to account for the difference in density to determine the equivalent rotameter scale 
reading. This factor, called the gas correction factor (GCF), is defined by King Instruments as follows 
in Equation [ 1 ] and is dependent on the gas specific gravity, gsp, temperature in Kelvin, T, and the 











 [ 1 ] 
By multiplying the desired flow rate of CO2 by this GCF, and then correcting this flow value for the 
rotameter's calibration error, the scale reading required to give a CO2 flow desired could be found. As 
the GCF has a small dependence on temperature it was calculated on each day of testing to account 
for daily variation. 
5.4.2 Experimental Method Version One Specific Components 
The system components described in this section are specific to the CO2 washout experiments 
undertaken using Experimental Method Version One as described in Chapter 9. Combined with the 
CO2 feed described above and the permanent system components these elements make up the full 
experimental system employed. 
Pump to Airway Model Intermediary Connections 
As the purpose of this method was to measure the rate of CO2 concentration decay and how this was 
affected by Optiflow™ NHF, it was not imperative that the system accurately replicated the 
respiratory system. As such much of the initial system setup, including the original pump form with 
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the cone exit and many industrial connections, was employed. As for the pressure and turbulence 
measurements, the pump was connected to the airway via a series of flexible tubing and a straight 
pipe; however, in this system another flexible tube was added to the system to allow for the inclusion 
of the carbon dioxide sensor. This is illustrated in Figure 17. 
Figure 17: Schematic of Experimental Method Version One experimental system. 
Carbon Dioxide Sensing Element 
As the measurement of CO2 concentration decay was not representative of a physiologically realistic 
phenomenon, it was decided the level of CO2 concentration added to the model for measurement 
could be any detectable amount which would not cause a safety risk to those in the vicinity of the 
experiment. This measurement method was also to be an initial foray into the detection of gas 
concentrations in the experimental system, and a means of developing an accurate method for 
measuring CO2 washouts in vitro. For these reasons it was concluded that low cost was a principal 
requirement in the gas sensor selection process. Also of high importance was the sensor sampling rate, 
response time, ease of calibration and accuracy. The period of the breath flow wave to be employed 
for these measurements was 5.08 seconds thus a sampling rate less than this was desired. As the decay 
rate of the CO2 was yet unknown it was uncertain what response time would be adequate for the 
measurements.  
From these criteria the GE Telaire Ventostat T8041, an optical CO2 sensor designed for monitoring 
air duct concentrations, was selected as it had the best measurement range, sampling rate, response 
time and accuracy of the sensors in the low-price range considered at the time of purchase. Calibration 
of the sensor was completed in the factory with no other calibration required over the sensor lifespan 
of 15 years. The most important specifications of the sensor are listed in the following Table 2. 
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Table 2: Details of the GE Telaire Ventostat T8041 CO2 sensor. 
The sensing element of the Ventostat is located within a cylindrical probe limb with a diameter of 
31.5 mm, too large to introduce directly into the connections between the pump and airway which 
were all approximately 20 mm in diameter. Two sets of perforated holes each covered a small, square 
area along the length of the probe allowing air to access the sensing element. To incorporate the 
sensing element of the Ventostat into the system, the limb was mounted perpendicularly to a piece of 
straight tube, 22.5 mm in diameter, so that the two intersected by a short depth with the tube passing 
across one set of perforated holes. The second set of perforated holes which lay exterior to the flow 
path was sealed. The tube could then be fitted in line with the connections between the pump and the 
airway, as illustrated in Figure 18. 
Figure 18: Incorporation of Ventostat T8041 CO2 into experimental system. 
5.4.3 Experimental Method Version Two Specific Components 
The system components described in this section are specific to the CO2 washout experiments 
undertaken using Experimental Method Version Two as described in Chapter 9. Combined with the 
CO2 feed described above and the permanent system components these elements make up the full 
experimental system employed. 
Pump to Airway Model Intermediary Connections 
As mentioned in the pump description, accurate replication of the human respiratory system volume 
was important for the measurement of the CO2 washout using the temporal averaging method. The 
Cost Measurement Range Sampling Rate Response Time Accuracy 
$436.59  
(NZD) 
0 - 2000 PPM 0.5 Hz 
3 minutes  
(For 90 % step change at 
low flow speeds) 
± 40 PPM  
+ 3 % of reading 
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geometry of this volume, particularly the separation of the anatomic dead space volume from the lung 
volume, was equally important as it was found that with the original pump cone outlet and step down 
connections containing some of the FRC the CO2 profile at the airway model nares deviated 
significantly from that of a live subject. With the new flat plate ended pump design all system 
components outside of the pump; that is the airway, sensing elements and connections; made up the 
entire volume of the anatomic dead space. Between the airway and the pump the small amount of 
remaining dead space volume consisted of two consecutive gas sensor connections from the pump 
followed by a short length of straight 22.5 mm inner diameter tube attaching to the airway model. 
This is shown in the schematic of Figure 19. 
Figure 19: Schematic of Experimental Method Version Two experimental system. 
As the average anatomic dead space volume is commonly stated to be 150 ml for an adult (Tortora 
and Derrickson, 2006) the intermediary connections were made so that their volume when combined 
with the volume of the upper airway model would total 150 ml. As mentioned at the beginning of this 
chapter, airway 06B was used as the standard upper airway model for experiments and as such the 
intermediary connections were made to suit the volume of airway 06B. The four other unique upper 
airway models had volumes which varied slightly as given in Table 1 in Chapter 4; however, as this 
was a result of natural variance in airway geometry it was considered acceptable to maintain the same 
intermediary connections for all when investigating the difference in Optiflow™ NHF efficacy as a 
result of upper airway variation. If the volume of each model were to have an influence on the 




Carbon Dioxide and Oxygen Sensing Elements 
For the second CO2 washout measurement method the system was used to replicate the physiological 
process of respiration, including the level of CO2 gas exchange within the lungs. Subsequently, a gas 
sensor capable of measuring CO2 levels over the range of 0 to 5.2% was required (Tortora and 
Derrickson, 2006). As for the previous sensor, a sampling rate of less than the breath period (4.29 
seconds for the new average person breath wave to be used) was also of high importance. As this 
sensor needed to capture the variation in CO2 concentration over the breath wave it was also desirable 
for its response time to be less than period of the breath wave. Again the sensor cost, accuracy, and 
ease of calibration were also prominent considerations. 
From the sensors available within the budget at the time of purchase, a TDS0054 carbon dioxide 
optical sensor by Dynament was selected. This sensor was one of the only available within the range 
of the budget which met the measurement range requirements. Of these few it provided the best 
response time, sampling rate and accuracy. The sensor came pre-calibrated with a calibration check 
required after one year. A Senko SS1118 electrochemical O2 sensor with similar specifications was 
also purchased at the same time for use as a reference during testing. The notable specifications for 
each sensor are given in Table 3 and pictures of the sensors can be seen in Figure 20.  
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Figure 20: Gas sensors (a) Dynament TDS0054 CO2 sensor; and (b) Senko SS1118 O2 sensor. 
As shown in Figure 20, both the O2 and CO2 sensors were cylindrical and, as both had a 20 mm 
diameter, were easy to mount in line with the pump to upper airway model connections. To hold each 
sensor in line with the flow at its perimeter, identical plastic connections were designed and 3D 
printed. These connectors, pictured in Figure 21, were formed with tapers on each end, one external 
and one internal, so they could be easily joined to other standard connections in use. The openings for 
the sensors also had a slight taper to give a push fit for sealing and accurate placement of the sensor 
within the flow. 
 
Figure 21: Connectors for integrating CO2 and O2 sensors into the flow path of the Experimental Method 
Version Two system. 
These connectors provided a mounting for the two sensors allowing them to be incorporated into the 




6 Breath Pattern Development 
To provide an accurate representation of a human respiratory system a breathing pattern which 
replicated the form of an in vivo natural breath flow wave was desired. As described in the 
background theory there are two major components to the breathing pattern, the tidal volume and the 
respiratory rate. The form or shape of the breathing pattern itself is not symmetrical across inspiration 
and expiration due to the active and passive mechanisms of each respectively. A simple sinusoid 
waveform does not replicate this, thus in vivo breath pattern data acquired in previous research were 
used to form the flow patterns to drive the pump. The natural breathing pattern of a healthy 23-year-
old male subject, 84 kg with a BMI of 24.6, was captured at a rate of 100Hz by a TSI-4040 flow 
meter attached to the outlet of a full face mask worn by the subject. Further breathing patterns of the 
subject were captured while receiving a range of NHF therapy levels with the Optiflow™ cannula 
worn underneath the mask. The applied flow rates of the Optiflow™ NHF, ranging from 10 to 50 
LPM at intervals of 10 LPM, were subtracted from the captured data to extract the lung’s contribution 
to the flow. The final breathing flow rate results from these measurements are shown in the Figure 22 
plot where positive values show expiration and negative inspiration. 
Figure 22: In vivo breathing flow rates as measured from male subject while breathing naturally and 
with various levels of NHF therapy. 
This plot shows distinguishable changes to both the respiratory rate and the peak inspiration and 
expiration values with the use of Optiflow™ NHF therapy. A decreasing trend in the peak inspiration 
flow rate occurs with increasing levels of NHF, resulting from the assistive NHF flow. The increased 
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resistance to expiration from this flow also results in an increase in the period of each breath with 
increasing NHF flow rates.  
Initially these variations of the breathing pattern with varying NHF flow rates were considered an 
important aspect of the respiration characteristics which should be included in the experiments. The 
first sets of CO2 dead space washout experiments carried out using Experimental Method Version 
One were therefore done so with the breath flow wave provided matching the level of NHF therapy 
being administered. However, after further progression of the experimental system it was decided that 
the extent to which these variations occurred was most likely patient dependent like many other 
factors. Similarly, the in vivo measurements from which the breathing patterns were derived were 
performed on a healthy subject unlike the patients who usually receive Optiflow™ NHF therapy as 
they are experiencing some level of respiratory distress. Therefore it was decided that using a single 
breath wave pattern for all subsequent experiments would eliminate one variable, allowing for data 
measurement from which the effects of the NHF on flow and wash out characteristics alone could be 
determined. The natural breathing pattern was chosen for this purpose. 
At the same time as the decision was made to use the natural breath pattern for all future experiments, 
the magnitude of the tidal volume and respiratory rate were scrutinised. The tidal volume of the 
original natural breathing pattern, at 799 ml, was found to be above the average accepted value of 500 
ml although the respiratory rate was close to the standard 12 breaths per minute at 11.8 (Tortora and 
Derrickson, 2006). The greater tidal volume may in part be attributed to the method of measurement, 
as wearing the face mask with the attached flow meter effectively increased the subject’s dead space 
volume. Tobin et al. (1983) studied the breathing patterns of 65 adult subjects without altering the 
dead space volume and found an average respiratory rate of 16.6 breaths per minute and an average 
tidal volume of 383 ml. The difference in their measured tidal volumes and respiratory rates to the 
accepted average values were attributed to the experimental methods of previous studies in which 
dead space volume was added to the subjects by introduction of measurement equipment (Tobin et al., 
1983). When these factors were taken into consideration, it was concluded the original natural 
breathing pattern was not a faithful representation of an average adult and the pattern should be scaled 
down to do so whilst retaining a realistic form. Values of tidal volume and respiratory rate between 
those commonly accepted and those found by Tobin et al. (1983) were chosen, at 450 ml and 14 
breaths per minute respectively. This provided an 'average' or representative adult breathing pattern 
with a realistic waveform which was used for all experiments except the initial CO2 dead space wash 
out, Experimental Method Version One, and the measurements of turbulence intensity at the external 
nares. A comparison of the original natural breathing breath wave and the same breath wave scaled to 
the ‘average’ tidal volume and respiratory rate are shown in Figure 23. 
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Figure 23: Comparison of the original natural breathing breath wave as measured in vivo and the wave 
scaled to an average 450 ml tidal volume and respiratory rate of 14 breaths per minute. 
To convert the breathing data into a usable form to drive the pump, each set of data was phase 
averaged over twenty breaths and then converted into Fourier series. Conversion was done in Matlab 
by conducting spectral estimation on each breath pattern, followed by fitting of the strongest 
frequencies to a Fourier series from which the coefficients were extracted. A five coefficient Fourier 
series was determined for each set of breathing data. This was done for all breath waves employed 
throughout this research. This method provided close approximations of the measured data as shown 
in Figure 24 which gives a comparison of the ‘average’ natural breathing pattern to the Fourier series 
extracted from the same data.  






7 Static Pressures in the Upper Airway 
Prior research with the five early upper airway models employed in this research has identified that 
loss of pressure occurs in the upper airway when constant flow rates are used in place of oscillatory 
breathing flows. The static pressure results of these steady state experiments are shown in the Figure 
25 plot for the case of constant 20 LPM expiration flow through each of the five airway models. The 
pressure loss is a result of the airway resistance and is dependent on the geometry of the individual's 
upper airway. Viscous pressure losses occur due to friction at the airway walls while sudden changes 
in airway cross section induce flow separation resulting in further losses in pressure. Within the 
oropharyngeal region large changes are seen in the cross-sectional area due to protrusion of the uvula 
and epiglottis thus high losses in pressure are expected to be observed. 
Figure 25: Static pressures observed during previous research in the five original airway models during 
steady-state experiments using a constant expiration flow rate of 20 LPM  
(adapted from Cressy et al. (2011)). 
The resistance to inspiration is believed to be reduced with the use of NHF therapy as a result of the 
NHF flow rate meeting or exceeding the peak flow rates required by the lung expansion. This 
subsequently reduces the work of inspiration, and is noted as the second mechanism of action for 
NHF therapy by Dysart et al (2009). This would be observed as an increase in static pressure within 
the upper airway during inspiration with increased levels of NHF therapy. It has previously been 
found that during inspiration healthy, live subjects experience an increase in resistance due to the 
distensibility of the nasopharynx and the vacuum pressures of inspiration resulting in a decrease in 
airway patency (Shepard and Burger, 1990). Due to the rigidity of the models used in these 
experiments the occurrence of this phenomenon and its effects were not observed; however, as NHF 
is expected to increase pressures, thus reducing the forces which act on the airway walls to reduce 
patency and increase flow resistance, any reduction in resistance observed in vitro will be 
conservative. Similarly, the point at which inspiratory work drops to zero with the NHF flow fully 
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fulfilling the peak flow requirements will be the same as it would be in a compliant model. 
Measurements of the static pressure at numerous positions within the upper airway were undertaken 
to determine the influence of the use of Optiflow™ NHF therapy. These measurements were also 
utilised later to draw conclusions about the relationship between airway pressures and CO2 dead space 
wash out.  
Dysart et al. (2009) postulated that the positive airway pressure induced by the flow of NHF provides 
a distending pressure to the lungs and consequently improves lung recruitment, listing this as the fifth 
mechanism of action. Due to the rigid nature of the experimental system, in particular the lung pump, 
this affect cannot be investigated; instead the pressure losses and generation of positive airway 
pressure due to NHF therapy within the rigid airway region are explored. 
It is thought that the pressure loss observed in the pharynx is an indication of the presence of 
turbulence, which is believed to have positive effects on dead space wash out by promoting mixing. A 
decrease in airway pressure during inspiration and an increase in airway pressure during expiration 
may then be the result of an increase in the level of turbulence. Measurements of pressure in the 
airway, particularly those surrounding the velopharynx, were also later compared to the results of 
turbulence intensity measurements across the velopharynx cross section. 
7.1 Experimental Procedure 
To measure the behaviour of the static pressures within the upper airway during oscillatory flows data 
was collected at 21 different positions over many cycles for both natural breathing and breathing with 
Optiflow™ NHF. The standard airway 06B model was employed and the experimental respiratory 
system was prepared as described in Chapter 5. The regions of the upper airway and static pressure 
measurement positions, focusing predominantly on the pharynx, are shown in Figure 26.  
Before starting the experiments the pressure sensors were zeroed. The pump was run with the average 
adult breath flow wave, with 450 ml tidal volume and respiratory rate of 14 breaths per minute. The 
experiments were conducted for natural breathing and breathing with Optiflow™ NHF flow rates 
from 10 to 70 LPM in 10 LPM increments. Measurements of the static pressure at all 21 points were 
simultaneously collected for a period of five minutes at a rate of 100 Hz, with data collection 





Figure 26: Right side views of airway 06B silhouette showing (a) regions of interest in the upper airway; 
and (b) pressure taps locations where lines normal to airway surface show posterior, anterior, inferior 
and superior taps while crosses and circles mark lateral taps. Lateral and side-by-side taps are coloured 
red and yellow to indicate right and left positions respectively. 
7.2 Data Processing 
As the raw pressure data collected contained some noise, an average transient static pressure profile 
over a single breath period was extracted by phase-averaging 20 cycles of data together. By splitting 
the breath cycle period into a discreet number of phase points, the values of pressure at each phase 
could be averaged together. As the breath wave period was not a multiple of the data collection 
frequency, a linear interpolation method was used to estimate the static pressures at each phase. 
Subsequent to data collection it was discovered a number of the cycles in each dataset had been 
clipped. Consequently it was necessary to manually check each set of data and extract 20 full cycles 
for phase-averaging. The beginning of each full cycle was determined by manual identification of the 
minimum flow rate prior to expiration onset from the simultaneously acquired pump flow data. 
Matlab was then employed to carry out the phase-averaging process. This produced smooth profiles of 
the large-scale transient pressures occurring at each of the measurement positions over the course of a 
breath cycle.  
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7.3 Results and Discussions 
The experimental results described following are separated into two sections, the natural breathing 
results and the results of breathing with NHF therapy. 
7.3.1 Natural Breathing 
During natural breathing the static pressure at each point of measurement within the upper airway has 
a form similar to that of the breath flow wave. Positive pressures were measured during expiration and 
conversely negative pressure during inspiration. Overall the pressure wave appears in phase with the 
flow wave as illustrated by the results from a single measurement position in Figure 27; however, 
throughout the transition from expiration to inspiration the pressure lags the flow wave, in particular 
during the steep acceleration to peak inspiration. This is also shown in Figure 27 where it can be seen 
that the inspiration portion of the breath cycle is shorter than expiration and achieves higher peak flow 
rates, thus the steeper curve.  
Figure 27: Transient static pressure at the anterior nasopharynx and scaled flow rate during natural 
breathing showing pressure lagging flow at the drop to peak inspiration. Flow rate scaled by a factor of 
0.479 Pa/LPM. 
In general the absolute magnitudes of peak expiration and inspiration pressures increase as the 
measurement points move towards the lungs, though some local decreases in magnitude are also seen. 
This result is indicative of the airway resistance that opposes the flow and causes pressure loss 
between the lungs and the external nares. The presence of airway resistance contributes to the work of 
breathing, with greater effort required to breathe for greater levels of resistance.  
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The transient static pressures at the superior nasopharynx follow a profile very similar in form to the 
flow rate curve with very close agreement between the ratios of peak inspiratory to expiratory values. 
This is illustrated in Figure 28 in which the flow rate curve has again been normalised by the peak 
inspiratory pressure for ease of comparison. This indicates that the pressure drop across the nasal 
cavity between the external nares and the point of measurement is related to the flow rate by a similar 
factor for both expiration and inspiration. Specifically, this implies that the flow resistance within the 
nasal cavities is similar in both flow directions, agreeing with the steady-stated in vitro findings of 
Croce et al. (2006). As previously mentioned, in vivo research has shown that in live subjects an 
increase in resistance is seen during inspiration due to the compliance of the nasal vestibule and later 
the nasopharynx (Shepard and Burger, 1990). This highlights a limitation of the use of rigid airway 
models as deformation of the airway is prevented and this change in resistance during inspiration is 
not replicated in the results. 
At the superior trachea the flow rate and pressure ratios of peak inspiratory to expiratory values do not 
show the same agreement seen at the superior nasopharynx. This is shown in Figure 29 where the 
flow rate curve has been normalised by the peak inspiratory pressure as before. From this result it can 
be deduced that there is a slightly greater resistance to flow across the entire upper airway during 
inspiration than during expiration.  
Between the superior nasopharynx and the trachea there is a large pressure drop during inspiration as 
illustrated by the plot of the peak static pressures at all measurement points in Figure 30. This drop 
begins as the cross-section of the airway decreases toward the minimum cross section at the 
velopharynx. Past the velopharynx a large irregular cavity appears on the anterior wall formed by the 
uvula, tongue and epiglottis in superior to inferior order. Another cavity is formed at the inferior 
region of the laryngopharynx below the anterior opening to the larynx. The superior of these cavities 
causes an expansion of the pharynx cross-section in both expiration and inspiration directions, 
however only expiration flow experiences a slight pressure recovery at this cross-section widening, 
whilst a slight drop in pressure is seen for the inspiration flow. Inspiration pressures have an overall 
downward trend along the flow path while in comparison expiration shows large drops in pressure 
with frequent recoveries. 
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Figure 28: Transient static pressures at the superior nasopharynx during a natural breathing cycle 
showing close agreement in peak magnitudes to the normalised flow rate. Flow rate scaled by a factor of 
0.432 Pa/LPM. 
 
Figure 29: Transient static pressures at the perimeter of the superior trachea during natural breathing in 




Figure 30: Expiration and inspiration peak static gauge pressures at every pressure tap location with 
anatomic regions labelled. 
In the same region between the superior nasopharynx and the trachea the pressure drop experienced 
during expiration is significantly lower relative to the flow rates achieved. While the nasopharynx to 
laryngopharynx region causes large losses during peak inspiration, the losses during peak expiration 
are not equivalent as shown previously in Figure 30. Research by Stringer et al. (2010) which 
simulated steady state flow within the same airway showed that during peak expiration the flow is 
directed from the anterior opening of the larynx into the pharynx, illustrated in Figure 26 (a), in a 
superior-posterior direction as given in Figure 31 (b). The flow path is jet-like within the pharynx and 
has little interaction with the two large cavities, unlike the flow path during peak inspiration in Figure 
31 (a) which shows streamlines more evenly spread across the pharynx cross section and interaction 
with both cavities. This difference in the flow distribution across the pharynx gives some explanation 
as to the differences seen in the pressure losses. As the flow passes from the velopharynx into the 
inferior nasopharynx during expiration there is a small recovery of pressure due to the smooth 
expansion. This is shown in Figure 32 by the increase in the expiration curve peak between the 





Figure 31: CFD results of steady state flows through airway 06B showing streamlines in m/s for (a) peak 
inspiration flow of 22 m/s and (b) peak expiration flow of 32 m/s (adapted from Stringer et al. (2010)). 
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Figure 32: Transient static pressures at the posterior velopharynx and posterior-inferior nasopharynx 
showing small recovery of pressure during expiration. 
7.3.2 Breathing with Optiflow™ NHF Therapy 
With the introduction of NHF therapy the transient static pressure profiles are seen to move upwards 
on the vertical axis in the positive pressure direction. The mean, peak expiration and peak inspiration 
static pressures become more positive with increasing levels of NHF therapy. An example of this is 
given in Figure 33 which shows a plot of the transient static pressures at one of the superior trachea 
measurement positions for all levels of NHF. At this position, the most inferior measurement point in 
the upper airway model, the inspiration peak static pressure first crosses the horizontal axis into the 
positive pressure region for a NHF flow rate of 30 LPM. This implies that with a NHF flow rate of 30 
LPM the upper airway resistance to flow during inspiration is fully compensated for by the inward 
flow of air supplied by the NHF therapy. Therefore at this flow rate the work required to draw air 
from the external nares to the trachea entrance would be fulfilled by the NHF therapy, reducing the 
overall inspiratory effort required by the lungs. This is in line with the second theory from Dysart et 
al. (2009) that by providing flows equal to or in excess of the peak inspiration flow rate, in this case 
22.1 LPM, the airway resistance is fully compensated by the NHF. For the maximum flow rate tested 
of 70 LPM the mean static pressure at the trachea measurement position in Figure 33 had increased 
from 0 to 300 Pa (gauge). The increase in the peak static pressure of expiration however shows that 
there is increased resistance to flow out of the lungs. In live subjects this increased resistance would at 
some NHF level surpass the physical effort which can be provided by the passive elastic tension of the 
lungs and internal intercostal muscles and expiration would necessarily become an active process 
instead of a passive one. The point at which this would occur cannot be the determined from these 
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results as the elastic properties of the lungs were not replicated in these experiments, nor is the 
resistance of the conducting airways below the upper airway known. The effect of this increased 
expiratory resistance is of interest as persons suffering from COPD and other respiratory diseases who 
may receive Optiflow™ NHF therapy as a treatment often have increased airway resistance or 
reduced lung elasticity as a result of their condition. Therefore it is likely that there is a point at which 
increasing the NHF flow rate further has a detrimental effect rather than a positive one. 
Figure 33: Transient static pressures at the posterior-superior trachea for natural breathing and all 
Optiflow™ NHF flow rates showing increase in mean, peak expiration and peak inspiration pressures 
with increasing NHF flow rates. 
The increase of the peak and mean static pressures with increasing levels of NHF can also be seen in 
Figure 34. This gives a plot of the averages of mean, peak inspiration and peak expiration static 
pressures measured at the four trachea pressure taps as a function of the NHF flow rate. All three can 
be closely approximated by a second order polynomial. The peak inspiration and expiration curves are 
divergent within the range of tested NHF flow rates, with the difference between the peaks becoming 
greater with increasing NHF levels. This implies that within this NHF range the expiratory resistance 
grows at a faster rate than the inspiratory resistance declines. In other words the beneficial effects of 
Optiflow™ NHF therapy during inspiration develop more slowly than the detrimental effects during 
expiration with increasing therapy flow rates. 
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Figure 34: Plot of peak expiratory, peak inspiratory and mean static pressures at the trachea 
measurement locations for natural breathing and all NHF flow rates with second order polynomial fits. 
As the general form of the pressure wave remains the same with increasing levels of NHF, an attempt 
was made to design an equation by which the natural breathing pressure wave could be adjusted to 
approximate the pressure wave at any level of NHF therapy. The second order polynomial fit from the 
Figure 34 plot was used calculate the mean position of the static pressure wave. A power relation of 
the form yNHF=x = y0Ax
b
 was employed to describe the static pressure at each phase position as a 
function of the natural breathing pressure at the same phase, y0, and the NHF flow rate, x. It was 
found that the static pressure relationship to the NHF flow rate was not linear but rather a power 
where a value b = 0.65 provided the best fit. As expiration and inspiration peaks grow at different 
rates, the constant A was assigned two values of 0.33 for expiration and 0.28 for inspiration. The 
equation is therefore:  
 
)5793.35896.00551.0(y 265.00xNHF  xxAxy
 [ 2 ] 
Equation [ 2 ] produced close agreement to the measured static pressure waves at 10 and 70 LPM 
NHF, and reasonable agreement at the intermittent NHF flow rates. The largest relative differences 
between estimated and actual transient pressures occur for 20 LPM NHF. Figure 35 shows the 
comparison plots of the estimated and actual transient pressures for 70 LPM and 20 LPM illustrating 
the predictive ability of the approximation formula. It must be noted that this formula is only 
applicable to this particular airway model and breathing pattern for the specific range of NHF flow 
rates from 0 to 70 LPM. Similarly, it is only valid for approximating the static pressures at the 
superior trachea position from the static pressures measured at the same position during natural 
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breathing as other regions show different losses and would require different expiration and inspiration 
specific values for the constant A. 
(a) 
(b) 
Figure 35: Plots of actual measured transient static pressures and the transient static pressures estimated 
using natural breathing data and Equation [ 2 ] for (a) 20 LPM showing the major differences and  
(b) 70 LPM showing close agreement. 
With the introduction of increasing levels of Optiflow™ NHF therapy there is an increase in the 
pressure drop across the upper airway for both inspiration and expiration phases as previously shown 
in Figure 34. Relative to the flow rates of breathing achieved during each phase, expiration pressures 
losses surpass those of inspiration, in contrast to the greater relative pressure losses seen during 
inspiration for natural breathing. With the increase in flow resistance during expiration due to the 
inward flow of the NHF this is an expected outcome. Figure 36 illustrates this in a plot of the flow 
rate alongside the static pressures at the superior trachea measurement positions for 70 LPM 
Optiflow™ NHF therapy. The flow rate curve has been shifted up the y-axis to match the x-axis to the 
mean pressure and normalised by the peak inspiratory pressure allowing for the flow and pressure 
58 
 
profiles to be easily compared. Unlike the equivalent natural breathing plot in Figure 29 where the 
flow curve was greater than the static pressure curves during expiration, here the static pressure 
curves exceed the flow implying greater resistance to expiration flow. 
Figure 36: Transient static pressures at the perimeter of the superior trachea during breathing with  
70 LPM Optiflow™ NHF therapy in comparison to the flow rate illustrating increased expiratory 
pressure loss. Flow rate scaled by a factor of 4.212 Pa/LPM and shifted up by constant 299.93 Pa. 
7.4 Conclusions 
Measurements of the static pressures at numerous positions within the upper airway 06B model were 
performed for natural breathing and breathing during Optiflow™ NHF therapy. During natural 
breathing the peak static pressures within the upper airway were seen to increase in magnitude in the 
direction of the trachea with local fluctuations. The form of each static pressure wave observed was 
overall in phase with and similar to the flow wave produced by the pump. Peak expiratory and 
inspiratory pressures at the superior nasopharynx, just posterior to the nasal septum, were related to 
the flow by a very similar factor implying that resistance across the nasal passage was the same in 
both flow directions. This agreed with the in vitro findings of Croce et al. (2006) but is contrary to in 
vivo measurements which have found that patency of the compliant nasal vestibule is decreased 
during inspiration leading to a slightly greater resistance than expiration (Shepard and Burger, 1990). 
Peak static pressures at the superior trachea during natural breathing inferred that the entire upper 
airway exhibited a higher resistance to inspiration than expiration. Analysis of the airway geometry 
concluded that this was due to the expiratory flow experiencing more recoverable pressure losses, 
most notably at the expansion into the nasopharynx. 
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Implementation of Optiflow™ NHF therapy during natural breathing flows generated an increase in 
the mean and peak static pressures and a deepening of the pressure amplitude at all pressure taps. 
Peak inspiratory static pressure at the superior trachea became less negative with increasing NHF flow 
rate, first crossing the horizontal axis and taking on a positive value for a therapy flow rate of 30 
LPM. Thus at a flow rate of 30 LPM Optiflow™ NHF therapy fulfilled the inspiratory resistive work 
requirements of the upper airway. At the maximum tested NHF flow rate of 70 LPM the mean static 
gauge pressure at the trachea measurement positions had risen from 0 Pa during natural breathing to 
300 Pa. For the NHF therapy flow rates tested from 10 to 70 LPM the general form of the transient 
static pressure curve remained similar to that for natural breathing and could be reasonably well 
approximated by scaling and translating the natural breathing curve. This was exemplified by 
determination and application of Equation [ 2 ] for the approximation of static pressures at the 
superior trachea as a function of NHF flow rate. Though the implementation of NHF therapy was 
found to decrease inspiratory work with increasing flow rate it also caused increasing resistance to 







8 Turbulence Intensity in the Upper Airway 
It is hypothesised that the level of CO2 wash out achieved by Optiflow™ NHF therapy has a relation 
to the air velocity within the airway and the turbulence of the flow through the pharynx. Turbulence in 
a flow improves the level of mixing and in the case of NHF it was postulated that turbulence within 
the airway would help to disturb pockets of trapped exhaled gases, flushing them out and preventing 
them from being re-inhaled. It was also thought that the flow velocity exiting the cannula could be 
related to the level of flushing achieved, as with higher jet velocities from the cannula it is possible 
that the flow stream would penetrate the airway to a greater depth. The greater the depth of jet 
penetration, the greater the volume of the airway that is flushed of CO2 rich exhaled gases.  
It is thought that in the pharynx the flow regime may be transitional due to the presence of vortices 
induced by the protrusion of the epiglottis into the flow path and a turbulent jet through the pharynx 
on expiration (Jeong et al., 2007, Shinneeb and Pollard, 2012). There has been some support for this 
notion from previous measurements of static pressure within the same airway models employed 
within this research (Cressy et al., 2011). These measurements showed a large pressure drop occurring 
in the pharynx when steady, constant expiratory flows were passed through the five airway models. 
Hot wire anemometry was employed to further examine the velocities within the airway models and 
investigate the presence of turbulence during both natural breathing and breathing with Optiflow™ 
NHF therapy.  
8.1 Turbulence and Turbulence Intensity 
A turbulent flow regime is characterised by chaotic instabilities in flow velocity with both time and 
space, often seen as vortices and eddies within the flow stream. When a flow encounters a sudden 
change in geometry, such as the protrusion of the epiglottis into the pharynx, turbulence may be 
induced in the downstream flow. A flow's regime is often described by its Reynold’s number, the ratio 
of the inertial forces to the viscous forces, defined by the following Equation [ 3 ]. A low number 
indicates the predominance of viscous forces and subsequently a laminar flow. Conversely, a high 





[ 3 ] 
However, for a complex flow domain such as an upper airway, the occurrence of turbulence cannot be 
predicted confidently by the Reynold's number, nor can the Reynold's number describe the magnitude 
of the turbulence. Turbulence intensity, which can be experimentally determined, is a relative measure 
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of the level of turbulence in a flow. It is defined as the ratio of the root mean square (rms) velocity, 
Urms, to the mean velocity of the flow, Umean. This is illustrated in Figure 37 below and is defined by 
Equation [ 4 ]. 
Figure 37: Illustration of a turbulent velocity profile showing mean and rms velocities  









[ 4 ] 
Turbulence intensity was chosen as the measure for evaluating the turbulence within the airway as it 
was possible to measure both the mean and rms velocities at locations within the airway by the use of 
hot wire anemometry. As the determination of turbulence intensity requires a mean flow velocity and 
the flows examined were to be transient, only the small regions of peak inspiration and peak 
expiration were examined where the flow acceleration could be said to be momentarily zero. As 
measurement of the mean velocity was a necessary component of turbulence intensity determination, 
the peak inspiration and expiration mean velocities observed during all measurements are also 
examined and discussed within this chapter. 
Hot Wire Anemometry 
Hot wire anemometry is a commonly used technology for measuring turbulent flows as the method of 
sensing is highly responsive to velocity fluctuations. The sensing element, in the form of a probe, is 
also very small with a shaft diameter of only 1.9 mm. Both of these attributes make hot wire 
anemometry ideal for measuring turbulence intensity within the small volumes of the pharynx.  
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Hot wire anemometers measure velocity by employing the principles of heat convection and Ohm's 
law. The probe consists of a fine platinum-plated tungsten wire filament, 5 μm in diameter, suspended 
between two thin metal posts 1.25 mm apart forming an electrical pathway between them. The probe 
is connected to a control box where it forms part of one arm of a Wheatstone bridge. The control box 
electrifies and regulates the current supplied to the probe maintaining the filament at a constant 
resistance and subsequently a constant temperature. By measuring the bridge voltage, which 
constitutes the heat transfer, the air velocity can be determined using the known heat transfer 
properties of the filament and the air.  
Each probe is known to have a particular voltage to velocity curve. Due to the delicate nature of the 
probe filament it is susceptible to small changes in its heat transfer properties with exposure to 
airborne debris during testing. A simple two-point probe calibration can be carried out prior to testing 
to account for this and bring the curve into alignment. To do this two flows of known constant 
velocities, one at the upper and the other at the lower end of the probes measuring range, are passed 
over the probe and their respective voltages are captured. The voltage-velocity curve is then fitted to 
these two calibration points. 
8.2 Experimental Procedure 
Two different sets of velocity and turbulence intensity measurements were carried out focusing on 
two anatomic regions. The first set concentrated on the velocities and turbulence intensities of flows 
passing through the nares and how these differed between each naris of the same airway and further 
how they were affected by changes to the upper airway geometry. These experiments required the use 
of the five different upper airway models but excluded use of Optiflow™ NHF therapy. 
Measurements were also made on two live adult subjects as a comparison to the controlled in vitro 
environment. Optiflow™ NHF therapy could not be employed for these experiments as the cannula 
prongs occlude much of the central area of each naris thus preventing placement of the hot wire 
probe. The second set of measurements looked more closely at the turbulence intensity within a single 
airway, mapping the variation along an anterior to posterior traverse of the velopharynx. Optiflow™ 
NHF therapy was introduced to these experiments to investigate how this turbulence intensity profile 
along the traverse differed when increasing levels of NHF therapy were applied to the model. This 
experiment utilised only one of the upper airway models, the standard airway 06B model, and various 
levels of Optiflow™ NHF therapy. Both experiment sets required slightly different procedures as 
defined in the following sections; however, the hot wire probe calibration and data acquisition 
methods were the same for both. 
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8.2.1 Probe Calibration 
As described above there is a known relationship between the velocity of the air flow past the probe 
and the measured bridge voltage, which depends on physical properties of the system. As a result of 
using the probe in an open air environment its resistive properties can differ from use to use. 
Subsequently it was necessary to calibrate the probe regularly to ensure that measurements recorded 
were accurate, in this case on a daily basis before each use. 
The Dantec Dynamics hot wire calibrator was used to calibrate the probe with the two-point 
calibration described above. Compressed air was supplied to the calibrator and metered to one of two 
constant, factory-set velocities, denoted as low and high and selected with a lever handle on the 
calibrator. A needle valve could also be adjusted to provide additional flow velocities which could be 
determined using a pitot tube at the flow outlet. The hot wire probe was mounted above the flow 
outlet in a cradle and adjusted so that it was situated central to the orifice with the filament in line 
with the outlets upper surface. Once in place the probe was connected to the CTA control box and the 
current turned on. The system variables were input into the Dantec Dynamics software and the two-
point calibration program was run, where the bridge voltages were recorded for the low and high 
calibrator settings. The software then fit the curve to the calibration points and saved the calibration 
for subsequent measurements, thus completing calibration.  
8.2.2 Data Acquisition Setup 
As the turbulence intensity is defined as the ratio of the rms velocity to the mean velocity of the flow, 
the turbulence intensity of the oscillatory flow as a whole cannot be simply defined. Instead the 
turbulence intensity at characteristic regions of the flow, namely the peaks of inspiration and 
expiration, were investigated. At these peaks, where the flow acceleration drops to zero, there are 
short intervals of time where the mean velocity of the flow can be considered to be momentarily 
constant. It is for these short intervals of approximately constant velocity that hot wire data was 
desired. To capture the velocity fluctuations in the flow the data acquisition system of the Dantec 
software was set up to record a minute of data for each in vitro experiment at a sampling frequency of 
1 kHz. This set up allowed for the capture of multiple consecutive breath waves so that during data 
analysis the turbulence intensities calculated at peak inspiration and expiration could be averaged over 
a minimum of ten breath cycles. Data was captured for a shorter period of 20 seconds during in vivo 




8.2.3 External Nares Measurements 
To examine the levels of velocity and turbulence intensity which occur at the centre of the naris 
during natural breathing, both in vitro and in vivo experiments were performed. During in vitro 
experiments five unique airway models were employed, whilst two live subjects volunteered for the in 
vivo investigations. Individual measurements were performed at each naris, left and right, for all five 
airway models and the two live subjects. The procedures employed in vitro and in vivo are described 
separately below. 
In Vitro 
The five different upper airway models to be used for this first set of turbulence intensity experiments 
showed a wide variation in the size and geometry of the nares. Table 4 provides the average length of 
the major diagonal of the nares for each airway model as well as the major width of the base of the 
nose. All dimensions were measured from the physical models as illustrated by Figure 38.  
Table 4: Major measurements of the nares and nose of  
each airway model showing large variation in physical characteristics. 
 Average Major Naris Diagonal 
Length [mm] 
Major Width of the Base of the 
Nose [mm] 
Airway 06B
2 20.09 33.80 
Airway 07B 14.97 39.45 
Airway 09 13.23 30.86 
Airway 10 19.47 33.60 
Airway 16a 13.94 41.48 
 
Figure 38: Illustration of nose and naris measurement positions with naris major diagonal length shown 
by green arrows and major width of nose base shown by blue arrow. 
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Additionally each model had visible asymmetry between the left and right nares. As a consequence of 
this it was considered too complex to define a universal datum on the models' surfaces from which 
measurement positions could be specified. Similarly, it was decided that a single point measurement 
would suffice for each naris as defining a series of equivalent measurement positions across all 
models would be just as complex. Subsequently the positioning of the probe for each naris turbulence 
intensity measurement was set by eye. The probe filament was aligned with the centre of the naris and 
in line with the plane of the naris cross-section. This is illustrated in Figure 39 where the probe is 




Figure 39: Two views of the probe positioning central to the external naris opening of Airway 06B
2
 
Once the probe had been positioned the experiment was commenced by starting of the piston pump. 
During these tests the first generation of the breath flow waves, with the high tidal volume of 799 ml 
and breath period of 5.08 seconds as described in Chapter 6, was employed as it was the standard 
breath wave at the time. After a minute had passed to allow the system to settle into a consistent 
rhythm, data acquisition of the flow rate from the TSI flowmeter was initiated at the onset of an 
expiration, followed by hot wire data acquisition initiation at the onset of the next expiration. After 
completion of a minute of hot wire data acquisition flow rate logging was also terminated.  
In Vivo 
The turbulence intensity at the external nares of two adult subjects, one male (41 years, BMI of 21.5 
kg/m
2
) and one female (24 years, BMI of 18.8 kg/m
2
), were also measured for comparison to the in 
vitro experiments. Subjects were seated in an upright position with the head stabilised by an 
ophthalmology chin rest. Hot wire probes were positioned central to the outlet of each naris in the 
same manner as in vivo testing; however, due to the inability to completely fix the subjects' heads, the 
probes were positioned slightly farther from the nares to prevent probe damage. Due to the 
uncomfortable nature of the experiment and the possible adverse affects on the breathing pattern, data 
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was acquired for a minimum period of 20 seconds. Data acquisition was commenced at the onset of 
expiration as was the case for in vitro experiments. For all experiments subjects were encouraged to 
be relaxed and breathe naturally. 
8.2.4 Velopharynx Traverse Measurements 
Experiments to determine the turbulence intensity profile across an anterior to posterior traverse of the 
velopharynx in an airway model were performed for both the case of natural breathing and breathing 
with various flow rates of Optiflow™ NHF therapy. The purposed of these experiments was to 
determine whether the introduction of Optiflow™ NHF therapy increased the level of turbulence 
within the airway, specifically at the velopharynx, and how this possible increase may in turn be 
affected by the NHF flow rate. As it was the effects of the Optiflow™ NHF therapy on the turbulence 
which were under investigation, these experiments were performed using only the standard upper 
airway geometry, airway 06B.  
To allow for measurements to be made within the airway the original airway model, airway 06B
1
, was 
prepared with a small, 3.5 mm diameter hole entering into the posterior velopharynx central a 
transverse cross section. The length of this hole, from the entry point on the exterior model surface to 
its exit on the posterior velopharynx wall, was measured to be 11.40 mm for reference during traverse 
movements. Through this hole a hot wire probe was able to gain access to the full anterior to posterior 
diameter of the velopharynx. 
The model was set up in the experimental system for the turbulence intensity measurements as 
described in the Chapter 5. The probe support was mounted into the traverse mechanism clamp, as 
illustrated in Figure 40, and a shorting probe was installed into it. As can be seen in Figure 41, the 
shorting probe is a solid single prong, unlike the delicate hot wire probe, and as such could be used to 
accurately measure the depth to which the velopharynx could be accessed with the traverse. First, the 
probe was advanced until its end was flush with the exterior surface of the airway model and the 
traverse scale reading was recorded. The probe was then advanced through the hole until it met with 
the anterior surface of the velopharynx, once again recording the reading on the traverse scale. The 
difference between the two readings was then calculated as 21.40 mm, the maximum depth of the 
velopharynx. The difference between this depth and the depth of the hole, which equated to the 
straight line length between the anterior and posterior surfaces of the velopharynx, was also calculated 
at 10.00 mm. This length was divided into nineteen equally spaced measurement points, 0.05 mm 
apart, which began and ended 0.05 mm from the anterior and posterior velopharynx walls. 
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Figure 40: Probe support mounted into traverse mechanism positioned perpendicular to entry hole in 








Figure 41: Comparison of Dantec Dynamics (a) 55P11 probe used for measurements; and (b) shorting 
probe used to find position of anterior velopharynx wall (adapted from dantecdynamics.com). 
Once these critical dimensions had been found, the shorting probe was replaced with the calibrated 
hot wire probe. As with the shorting probe, this was advanced until it was flush with the exterior 
surface of the model and the traverse reading recorded. From this measurement, the traverse positions 
for each of the nineteen measurement points were calculated and the probe was advanced to the first 
and most anterior position. The clearance gap between the hot wire probe and the hole perimeter was 
sealed with Blu Tack at the exterior surface to prevent any flow from short-circuiting the airway path. 
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These more comprehensive measurements of turbulence intensity within the airway were performed 
during a later stage of the research than the external nares experiments and during the interval the 
breath flow wave had evolved to represent that of a more average human adult. Subsequently these 
experiments were conducted using the average breath flow wave with a 450 ml tidal volume and a 
breath frequency of 14 breaths per minute. Prior to beginning measurements the pump was allowed a 
minute of operation for the flow to settle into a consistent pattern. Data acquisition followed the same 
protocol described for the external nares measurements where TSI flow meter data logging was begun 
at the onset of an expiration cycle followed by the initiation of hot wire data acquisition at the onset of 
the next expiration cycle. At the conclusion of hot wire data acquisition, the flow meter data logging 
was stopped and the probe was moved to its next measurement position. The seal around the probe 
was assessed and adjusted as necessary before the data acquisition process was repeated. This was 
carried out until data for all 19 measurement points was attained.  
The first set of measurements did not employ Optiflow™ NHF therapy thus replicated a naturally 
breathing adult. For subsequent experiments the Optiflow™ nasal cannula was placed on the airway 
model and supplied with air flows as described in the Chapter 5. The turbulence intensities at the 
nineteen traverse positions were then re-measured following the same protocol above for all 
Optiflow™ NHF therapy flow rates assessed from 10 to 70 LPM at 10 LPM intervals. The use of 
NHF therapy is expected to alter the breathing patterns of the user when administered to live subjects; 
however this affect was not investigated as the breathing pattern employed remained constant 
throughout all experiments so that the influence of the NHF therapy on the velocities and turbulence 
could be observed. 
8.3 Data Processing 
To extract the mean and rms velocities from the peak inspiration and expiration hot wire data a few 
steps were necessary. First, the regions of interest over which the flow velocity could be considered to 
be constant had to be defined. Analysis of the breath flow waves used to drive the pump allowed for 
identification of regions of approximately constant flow rate and therefore flow velocity. These brief 
windows, defined in terms of milliseconds, were referenced from the instantaneous point of zero 
velocity at the beginning of the expiration portion of the curve. As two different forms of the breath 
flow wave were used, an older version for the in vitro nares experiments and the newest version for 
the in vitro velopharynx measurements, these regions were different in length but occurred at the 
same position relative to the period of the breath. The peak velocity regions evaluated for expiration 
and inspiration are highlighted on a plot of a natural breathing flow wave measured during an in vitro 
velopharynx experiment in Figure 42.  
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Figure 42: Flow rate profile of natural breathing flow wave illustrating regions used to determine 
turbulence intensity at peak expiration and inspiration. 
Manual triggering of the hot wire data acquisition meant that the raw data sets did not all start exactly 
at the beginning of expiration, the reference for the data analysis. Consequently, it was necessary to 
manually adjust some of the raw data sets accordingly before the peak inspiration and expiration 
regions could be extracted.  
Matlab was used to extract and analyse the peak inspiration and expiration regions from the data sets. 
For the in vitro experiments ten inspiration and ten expiration peak regions from every data set were 
reduced to mean and rms velocities. From these ten, an average mean and rms velocity and hence 
turbulence intensity were able to be calculated for each set of data. For the in vivo results only one 
inspiration and one expiration peak from each data set were analysed as fewer and less uniform breath 
cycles were captured due to the less controlled nature of the experiments. The formulae used to 
calculate the mean velocities, Umean, and rms velocities, Urms, are given as Equations [ 5 ] and [ 6 ] 
below, and from these values turbulence intensities were determined using the previously stated 




































8.4 Results and Discussions 
The experimental results described following are separated into two sections, the external nares 
measurements followed by the velopharynx traverse experiments. The external nares measurements 
are further divided into the in vitro and in vivo results, though comparisons are made between the two 
within the in vivo results subsection. 
8.4.1 External Nares 
In Vitro 
Figure 43 shows a plot of the first 25 seconds of raw hot wire anemometry data obtained from the 
right naris of airway 06B
2
 during natural breathing. This shows the raw velocities captured, beginning 
at the onset of expiration. Both expiration and inspiration are given as positive values due to the 
nature of measurement by hot wire anemometry which cannot determine flow direction, only 
magnitude. From just this raw data it can be seen that the velocity during peak expiration reaches a 
higher mean value than peak inspiration. Peak expiration also shows a much higher level of 
turbulence than peak inspiration as seen by the noise at the peak of the plot curves. 
Figure 43: The first 25 seconds of raw hot wire data acquired at the right naris of airway 06B2 during 
natural breathing. 
The mean velocities at each naris during the peak of expiration and inspiration were extracted from 
the five airway models hot wire anemometry data. These velocities have been plotted together 
identified by naris (left or right) and cycle peak (expiration or inspiration) in Figure 44.  
72 
 
Figure 44: Peak expiration and inspiration mean velocities at each naris averaged over ten breath cycles 
for each of the five airway models. 
Differences in mean peak velocity can be seen between both nares of each airway and also between 
expiration and inspiration peaks at the same naris. The mean velocity during peak expiration at each 
of the ten nares is greater than the mean velocity at peak inspiration for exactly half of the cases. 
Although there is an even split between which flow direction produced the greatest velocity 
magnitude, the velocity magnitudes found during peak expiration show a much greater spread than 
peak inspiration. Mean peak velocities of 0.87 to 3.47 m/s were seen across the airway models for 
expiration while inspiration mean peak velocities ranged from 1.31 to 2.50 m/s. It is known from 
other research that air is drawn into the nares from a hemispherical region surrounding the nose 
(Doorly et al., 2008b, Taylor et al., 2010) during inspiration. This provides a more even profile across 
the cross sections of the naris than expiration which produces a jet like profile on exit (Stringer et al., 
2010). Because the probe was positioned central to each naris by eye, it is likely that this position did 
not coincide with the centre of the expiration jet in all cases. This would explain the large variation 
seen in the expiration peak magnitudes. 
For each of the five different airways tested, the naris which exhibited the greatest mean peak velocity 
during expiration also had the greatest mean peak velocity during inspiration. Static pressure 
measurements in the airway 06B
2
 model indicated that the airway resistance through the solid model 
nasal cavity was equal for both inspiratory and expiratory flow directions. From these velocity results 
it is further implied this is true not only for the nasal cavity as a whole but for each side of the nasal 
cavity individually. The differences in the velocities seen at the two nares of each airway show a 
difference in the resistance in each nasal cavity with the flow favouring the path of least resistance. It 
is well known that for most adults the mucosal lining of the two sides of the nasal cavity swell and 
contract oppositely in a cyclic manner known as the nasal cycle. This process has a period of 
approximately three to seven hours and occurs such that the total resistance across the nasal cavity 
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remains almost constant (Baraniuk and Kim, 2007, Jones, 2001, Moinuddin et al., 2001). Four of the 
five airway cases showed the highest mean peak velocities at the right naris indicating that at the time 
they were subjected to the CT scanning process they had a higher resistance through the left side of 
their nasal cavity. 
A high level of difference is seen between the turbulence intensities of peak expiration and peak 
inspiration observed at the nares as illustrated in Figure 45. For all airway models turbulence 
intensities during peak expiration of at least 30% were seen at one naris, both nares in the case of 
airway 16, whilst no airway had a turbulence intensity exceeding 4% at either naris during peak 
inspiration. Overall very high levels of turbulence intensity were measured during peak expiration 
with a maximum of 46% observed at the left naris of airway 09. Conversely, peak inspiration 
presented low turbulence intensities for all airways with a maximum of 4% seen at left naris of airway 
16. These low levels of turbulence during peak inspiration agree well with the 2.5 % turbulence 
intensity found at the naris cross section of a 20 times scale nasal cavity by Hahn et al. (1993) during 
an average steady inspiratory flow rate. The presence of high turbulence in the case of peak expiration 
is an expected result due to the flow of expiration having the form of a jet created by the contraction 
at the nasal valve. As this jet passes through the nasal vestibule and exits the naris it exerts a shear 
force upon the relatively stationary mass of surrounding ambient air, causing a transfer of momentum 
and inducing turbulence. During inspiration however, air is drawn into the nares from the surrounding 
hemisphere with little disruption from the smooth profiles of the surrounding face. 
Figure 45: Peak expiration and inspiration turbulence intensities at each naris averaged over ten breath 
cycles for each of the five airway models. 
As with the mean velocities there is a large spread in the turbulence intensities observed at peak 
expiration. The breathing pattern used for this experiment was the same for all airways therefore any 
variation in the turbulence intensity is due to the geometrical differences in the airway models and 
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differences in the positioning of the probe. The geometry of the nasal valve and nasal vestibule would 
affect the velocity and profile of the expiratory jet and subsequently the turbulence intensity at the 
naris. Unfortunately another effect of the geometrical differences is the difficulty it causes in 
determining analogous measurement positions between the five models. It is possible that the 
differences seen are predominantly caused by the geometrical variation in the airway models, but it is 
also likely that they result from measurements being taken at only a single point with the probe 
positioned by eye. With such high levels seen at some airway nares it is highly likely that the 
turbulence intensity varies greatly across each naris cross section and the points of greatest turbulence 
intensity may not have been captured at each naris. Despite this some interesting points can still be 
drawn. 
Similar to the peak mean velocity results which showed a bias towards a single naris in both 
directions, the naris showing the highest turbulence intensity during peak expiration also showed the 
highest turbulence intensity during peak inspiration for four of the five airways. The exception to this 
was airway 16 which had the greatest turbulence intensity of 37% at the right naris during peak 
expiration, compared to 31% at the left, while during peak inspiration the left naris displayed the 
higher turbulence intensity of 4% in contrast to 2% at the right. Airway 16 is a unique geometry as it 
appears to be from a person of Polynesian or Micronesian descent based on facial features, unlike the 
other four airways which appear to be of European descent. Most importantly the profiles of the nares 
are significantly different as shown in Figure 46. This could be the source of the difference seen in 
turbulence intensity peaks between airway 16 and the four other airway models. 
Figure 46: View of the nares of each the five airways from left to right 06B, 07B, 09, 10 and 16 showing 
the significant difference in the form of the nares of Airway 16. 
Figure 47 shows the turbulence intensity and mean velocity observed at each naris of the five airways 
during (a) peak expiration and (b) peak inspiration. From plot (a) it can be seen that in three of the 
five airway cases the naris which produced the higher mean velocity showed the lower turbulence 
intensity during peak expiration. Similarly, plot (b) shows that the naris with the higher mean velocity 
during peak inspiration produced the lower turbulence intensity in four of the five airways. The mean 
velocity at the naris during both peak expiration and inspiration is therefore not an indicator of the 
magnitude of the turbulence. This is further confirmed by a plot of the turbulence intensity at each 






Figure 47: Comparison of turbulence intensity and mean velocity found at each airway naris during (a) 
peak expiration where mean velocity has been scaled up by a factor of 10; and (b) peak inspiration. 
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Figure 48: The turbulence intensity measured at each airway naris as a function of the mean velocity 
measured at the same naris for both peak expiration and peak inspiration illustrating the absence of a 
relationship for either. 
These two figures show that a high mean velocity at the measurement position is not indicative of 
high or low turbulence intensity at the same position for either peak expiration or inspiration. There is 
no discernible relationship between the mean velocity and the turbulence intensity. 
In Vivo 
The raw velocity data obtained outside the central nares of the two live subjects is plotted in the 
following Figure 49 with each series beginning at the onset of inspiration. It is immediately apparent 
that the velocity pattern at each measurement position has much greater variation from cycle to cycle 
than was seen in the controlled in vitro experiments. Results from the female subject also show a 
change in the period of the breath cycle between the measurements at the two different nares, whilst 
the breathing frequency of the male subject had close agreement of between the two. This discrepancy 
in the breathing frequency of the female subject indicates the effect of being conscious of observation 
on the breathing pattern. Despite the subject understanding the necessity to breathe as naturally as 
possible their breathing pattern was still affected.  
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Figure 49: Raw hot wire data from in vivo naris experiments showing wide variation in breathing 
patterns between male and female subjects. 
The magnitudes of the peak velocities at the nares also differ greatly between the two subjects with 
the male showing velocities no greater than 3 m/s while the female subject produced peak velocities 
exceeding 8 m/s during one expiration cycle. These very high peaks occur at both nares for only the 
first expiration of captured data and are not the mean peak velocities but the maximum velocities 
measured. Although the later expiration peaks measured on the female subject show lower and more 
regular velocities they are still in excess of those measured on the male subject. The differences in 
velocities between the two subjects are an indication in the wide variation in breathing patterns, tidal 
volumes and nasal geometries between the two. This validates the benefits of performing in vitro 
measurements with controlled breathing conditions as a means of observing the influence of airway 
geometry alone. 
As with the in vitro data, mean velocities at the peak of expiration and inspiration were extracted from 
the hot wire anemometry data; however, due to the more erratic nature of the breathing patterns only a 
single expiration and a single inspiration peak were evaluated from each twenty second dataset. The 
peak expiration and inspiration mean velocities for both subjects are plotted in Figure 50. 
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Figure 50: Comparison of the mean peak velocities seen at the nares of each in vivo subject for both peak 
expiration and inspiration. 
Comparison to the in vitro results shows that, like the airway models, the male subject shows the same 
velocity bias through one naris for both expiration and inspiration. The female subject however has a 
higher mean peak velocity of 4.59 m/s through the right naris during expiration but a greater mean 
peak velocity through the left on inspiration. This was not seen in any of the in vitro results and is 
perhaps a result of the probe being positioned eccentric to the expiration jet. As was seen in the raw 
data plot the female subject presents much higher velocities during expiration than the male subject. 
The inspiration mean peak velocities are much closer in magnitude. The mean peak velocities 
measured during the in vivo experiments show a slightly larger but similar range to the in vitro results 
as illustrated in Figure 51. 




The turbulence intensities calculated for peak expiration and peak inspiration from the in vivo data are 
plotted in Figure 52. As for in vitro turbulence intensities at the nares the peak inspiration values are 
lower than peak expiration. The range seen in vivo is however smaller than in vitro with a maximum 
turbulence intensity of 28.6% seen at peak expiration. Again it can be derived that the mean peak 
velocity observed at the naris does not give an indication of the turbulence intensity. 
Figure 52: Comparison of the turbulence intensities seen at the nares of each in vivo subject during both 
peak expiration and inspiration. 
Both peak inspiration and peak expiration in vivo turbulence intensities are similar to in vitro, as 
shown in the comparison of Figure 53. For peak expiration results from the male subject’s left naris 
showed the highest in vivo turbulence intensity of 28.63%. The maximum in vivo turbulence intensity 
during peak inspiration of 2.10% was conversely seen at the left naris of the female subject. The in 
vivo levels observed are all within the range found in vitro at the mid to low end. This may be the 
result of slight differences in the in vivo testing conditions in particular the positioning of the probe 
further from the nares than in vitro. This was necessary to prevent possible damage to the probe due to 
movement of the subjects’ heads. Positioning of the probe at a slightly farther distance from the nares 
would be expected to reduce the level of turbulence measured particularly for expiration, as the 
farther from the naris the lower the flow momentum and wider the jet. Another contributing factor is 
the more erratic nature of the raw in vivo data. Determination of the peak expiration and inspiration 
regions was far more difficult for these data sets as each curve was unique and, as was the case for 
expiration, the peaks were hard to identify amongst the turbulent noise. Subsequently, the regions 
chosen may not be analogous to those used to determine the turbulence intensities for the in vitro 
experiments. An observer bias may have also affected the results as regions were chosen based on 
how ‘average’ they appeared, thus noisier regions were avoided. It is also possible that the differences 
in rigidity and surface roughness of the nasal vestibule and valve between the rigid models and live 
subjects affected the hot wire anemometry measurements and caused the in vitro turbulence intensities 
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to be greater. This however cannot be confirmed as the rigid models are all of anonymous origin and 
too many other variables such as tidal volume and breathing frequency are present during in vivo 
experiments. The presence of higher temperatures in the in vivo expiratory flows may also help to 
suppress turbulence due to an increase in viscosity, however any viscosity increase would be slight as 
the higher humidity also present would prevent large viscosity increases (Tsilingiris, 2008). 
Figure 53: Comparison of in vivo turbulence intensities to in vitro for each naris at peak expiration and 
inspiration. 
In vivo results show similar patterns of high turbulence intensity during peak expiration and low 
during peak inspiration. The magnitudes of peak expiration turbulence intensities however are slightly 
lower in vivo than in vitro though in vivo levels still fit within the range seen in vitro. Again, there 
was no observable correlation between the mean peak velocities and the levels of turbulence intensity 
at each naris.  
8.4.2 Velopharynx Traverse Measurements 
Results from the airway 06B
1
 anterior to posterior velopharynx traverse were analysed to extract the 
peak expiration and inspiration mean velocities and turbulence intensities for each of the 19 
measurement positions. Figure 54 illustrates the location of the traverse line, shown in green, on a 
silhouette image of the airway 06B profile. The green line spans the entire anterior to posterior length 
of the velopharynx at the centre of the cross section, with the anterior and posterior sides marked with 
the letters A and P respectively.  
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Figure 54: Airway 06B silhouette illustrating position of traverse path used for in vitro velopharynx hot 
wire anemometry experiments. 
The mean peak velocities measured across the velopharynx traverse for peak expiration and peak 
inspiration during natural breathing are shown in Figure 55 with the distance from the anterior wall 
normalised by the length of the traverse so that 0 represents the anterior wall and 1 the posterior wall. 
A maximum mean velocity of 3.82 m/s was observed along the traverse during peak expiration whilst 
a smaller maximum of 3.02 m/s was measured during peak inspiration. 
Figure 55: Velocity profiles during both peak expiration and inspiration of natural breathing across the 
anterior to posterior velopharynx traverse where 0 represents the anterior wall and 1 the posterior wall. 
During inspiration the velocity profile has a more even distribution across the traverse when 
compared to expiration which exhibits a bias towards the central to posterior region of the 
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velopharynx. This result agrees with the steady state CFD work of Stringer et al. (2010), as mentioned 
in the static pressure results section, which illustrated inspiration flow distributed across the 
velopharynx while expiration flow was concentrated in a jet-like stream toward the posterior wall of 
the pharynx. Greater velocities through the velopharynx were achieved during peak expiration in 
comparison to inspiration despite peak inspiration reaching higher flow rates. These higher velocities 
during expiration were also observed in the steady-state CFD study of Stringer et al. (2010) as 
illustrated in the CFD results of Figure 56 which show the velocity profile through the same airway 
06B geometry at a sagittal section. The velocity magnitudes measured via hot wire anemometry are 
not as high as those found in the CFD analysis as a result of the CFD study being steady-state and 
employing different peak flow rates to those employed for the in vitro experiments. Significantly 
higher peak flow rates were used in the CFD study for expiration with a value of 32 m/s as opposed to 
the in vitro peaks of 13.5 m/s.  
(a) (b) 
Figure 56: Velocity map across sagittal section of the same airway 06B geometry as found by steady-state 
CFD analysis for (a) peak inspiration flow rate of 22 m/s; and (b) peak expiration flow rate of 32 m/s 
(adapted from Stringer et al. (2010)). 
With the introduction of Optiflow™ NHF therapy there is little change to the expiration velocity 
profile, as shown in Figure 57 which gives the expiration velocity profiles for natural breathing and all 
Optiflow™ NHF flow rates tested. With increasing levels of NHF therapy reductions are observed in 
the velocities in the centre of the velopharynx and dramatic increases in velocities are seen at the two 
most posterior measurement positions. The anterior region also shows decreasing velocities with 
increasing NHF flow rates for all except the maximum 70 LPM. This result infers that the flow of 
NHF produces more resistance at the anterior and central regions of the velopharynx, pushing the 
expiration jet closer to the posterior wall. The maximum mean peak velocity measured along the 
traverse shows very little variation from 3.82 m/s during natural breathing to 3.71 m/s during 
breathing with 70 LPM NHF therapy. 
On inspiration the changes to mean peak velocity are similarly small as given in Figure 58. With 
increasing levels of NHF therapy the velocity bias moves slightly further toward the posterior of the 
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velopharynx with small reductions in velocity at the anterior and slightly larger increases near the 
posterior. The use of NHF therapy projects the flow of air further toward the posterior with increasing 
flow rate. Contrary to expiration, during inspiration the maximum mean peak velocity along the 
traverse increases significantly from a natural breathing value of 3.02 m/s to 3.55 m/s for breathing 
with 70 LPM NHF therapy. 
Figure 57: Peak expiration velocity profile across the anterior to posterior velopharynx traverse for 
natural breathing and breathing with Optiflow™ NHF therapy flow rates from 10 to 70 LPM. 
 
Figure 58: Peak inspiration velocity profile across the anterior to posterior velopharynx traverse during 
natural breathing and breathing with Optiflow™ NHF therapy flow rates from 10 to 70 LPM. 
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The turbulence intensity profiles along the velopharynx traverse for peak expiration and inspiration 
during natural breathing are displayed in Figure 59. As was seen in the measurements at the external 
nares very high turbulence intensity levels are achieved during peak expiration in comparison to the 
relatively low levels for peak inspiration. The peak inspiration turbulence intensity profile is 
reasonably flat with peaks of 9% and 12% near the anterior and posterior walls which may indicate a 
turbulent boundary layer. During peak expiration flow high levels of turbulence intensity, with a 
maximum of 55%, were observed near the anterior velopharynx. The turbulence intensity 
distributions along the traverse for both peak expiration and inspiration also agree well with the steady 
state CFD results of Stringer et al. (2010) who mapped the turbulent kinetic energy (TKE) in a sagittal 
section as shown in Figure 60. These maps show that in the region of the velopharynx traverse there is 
very low, uniform TKE during inspiration and high TKE concentrated at the anterior and decreasing 
toward the posterior during expiration. The level of turbulence intensity during peak expiration 
exceeded that of peak inspiration for all traverse positions except the two most posterior.  
Examination of the airway geometry shows that the airway has a smooth contraction toward the 
velopharynx immediately above the traverse thus producing only low levels of turbulence intensity 
across it during peak inspiration. In the region below the velopharynx an irregular cavity is formed by 
the uvula, tongue and epiglottis on the anterior wall of the oropharynx. As the expiratory flow passes 
into the pharynx from the opening of the larynx in the anterior wall, the protrusion of the epiglottis 
further directs the jet toward the posterior. Above the epiglottis there is a sudden expansion into this 
aforementioned anterior oropharyngeal cavity promoting flow separation and turbulence. Turbulence 
is further exacerbated by the downward protrusion of the uvula into the anterior of the expiration jet 
path just below the velopharynx. This protrusion disrupts the expiration flow as it passes through the 
oropharynx into the velopharynx. These irregular geometrical features induce the high levels of 
turbulence measured in the anterior region of the velopharynx traverse. Less turbulence is seen during 
peak expiration from the centre to posterior of the traverse as the posterior pharynx has a much 
smoother form. The effect of this anterior oropharyngeal cavity on the turbulence during peak 
inspiration cannot be determined from the velopharynx traverse; however it is known from the static 
pressure experiments that a large pressure drop is seen between the trachea and velopharynx during 
peak inspiration and it is likely that this is in some part due to turbulence generated by this region, in 
particular the protrusion of the epiglottis. 
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Figure 59: Turbulence intensity profiles during both peak expiration and inspiration of natural breathing 








, across sagittal section of the same airway 06B 
geometry as found by steady-state CFD analysis for (a) peak inspiration flow rate of 22 m/s; and (b) peak 
expiration flow rate of 32 m/s (adapted from Stringer et al. (2010). 
Figure 61 shows that the introduction of NHF therapy generated little difference in the turbulence 
intensity profile measured along the velopharynx traverse during peak expiration. Increasing flow 
rates of NHF see a small reduction in the turbulence intensity near the anterior wall and an increase 
near the posterior. The peak of the turbulence intensity profile rises in magnitude with increasing 
NHF until it reaches a maximum of 59% at 40 LPM following which it begins to decline again. In the 
centre of the velopharynx higher NHF therapy levels gives generally greater turbulence intensity 
though this becomes less prominent further toward the posterior. When considering the mean 
velocities it can be deduced that the increase in the peak turbulence intensity occurs due to a 
significant decline in the mean velocity at this point without an equivalent decline in the rms velocity. 
That is to say that at this point the rms velocity did not increase significantly with increasing NHF 
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flow rates to provide higher turbulence intensity rather that the mean velocity decreased. The relative 
changes in turbulence intensity in the velopharynx during expiration with the use of NHF are low and 
thus is not likely a major contributor to the CO2 washout achieved by the Optiflow™ NHF therapy. 
Figure 61: Peak expiration turbulence intensity profiles across the anterior to posterior velopharynx 
traverse during natural breathing and breathing with Optiflow™ NHF therapy flow rates from 10 to  
70 LPM. 
The changes to turbulence intensity during peak inspiration show a more uniform increase across the 
entire anterior to posterior traverse with increasing NHF flow rates as shown in the plot of Figure 62. 
Again much greater increases are observed near the walls, the posterior wall in particular which rises 
from 1.5% during natural breathing to 51% with 70 LPM NHF. Away from the walls an average 
increase in turbulence intensity of 11% is seen between breathing naturally and breathing with 70 
LPM NHF. Considering the relatively low levels of turbulence observed during natural breathing this 
is not an insignificant increase, more than tripling the natural breathing peak inspiration average 
turbulence intensity. Though this increase in turbulence is unlikely to significantly improve the CO2 
flushing of the upper airway as it occurs during inspiration, the promotion of mixing may still prove 
beneficial by diluting any remaining pockets of CO2 rich gases which could be re-inhaled. 
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Figure 62: Peak inspiration turbulence intensity profiles across the anterior to posterior velopharynx 
traverse during natural breathing and breathing with Optiflow™ NHF therapy flow rates from 10 to  
70 LPM. 
8.5 Conclusions 
Hot wire anemometry was employed to measure velocities at the nares of the five unique airway 
models and two live subjects during natural breathing. Further measurements were carried out along 
an anterior to posterior traverse of the airway 06B
1
 velopharynx for natural breathing and breathing 
with Optiflow™ NHF therapy. From these measurements mean peak velocities and turbulence 
intensities could be extracted.  
The greatest mean peak velocities observed at the exterior nares occurred during peak expiration for 
both in vitro and in vivo experiments, attributed to the presence of a high velocity jet focussed from 
the nasal valve on expiration as opposed to a more uniform velocity profile on inspiration. A larger 
range of mean peak velocities were also seen during peak expiration than peak inspiration. It is 
believed that this is a result of the approximately central placement of the probe not coinciding with 
the centre of the expiratory jet for all nares. Maximum mean peak velocities of 3.47 and 2.50 m/s 
were seen for expiration and inspiration respectively across the five in vitro airway models. In vivo, 
the female subject exhibited very high mean peak velocities during expiration with a maximum of 
4.59 m/s. The naris which presented the highest velocity during expiration also produced the highest 
inspiration velocity for all in vitro experiments but only one of the two in vivo experiments. This 
implied that the path of least resistance through the two nasal cavity sides was the same in both flow 
directions, agreeing with the findings of the in vitro pressure investigations. A range of low to high 
levels of turbulence intensity were observed at the exterior nares during peak expiration for both in 
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vivo and in vitro conditions whilst peak inspiration produced low turbulence intensities. No 
discernible relationship could be found between the peak velocities and turbulence intensities 
measured at each individual naris. 
During natural breathing flow conditions the anterior - posterior traverse of the velopharynx found a 
more even velocity distribution at peak inspiration and higher maximum velocities during peak 
expiration. This aligned with the steady-state CFD findings of Stringer et al. (2010) where a high 
velocity jet was observed through the pharynx for expiration only. The introduction of NHF therapy 
had little influence on the velocity profiles, inducing a slight shift in the velocity distribution toward 
the posterior with increasing flow rates for both peak expiration and inspiration. Similarly, the 
expiration turbulence intensity profile was little affected by the introduction of NHF therapy, with 
increasing flow rates producing a slight decrease near the anterior wall and increase in the central to 
posterior region whilst the peak turbulence intensity remained in a constant location and was at a 
maximum for 40 LPM NHF. A more uniform increase was observed during peak inspiration with the 
average turbulence intensity away from the walls increasing triple fold between the conditions of 
natural breathing and breathing with 70 LPM NHF therapy. Though the changes in turbulence 
intensity with increasing levels of NHF therapy were small for peak expiration and are thus unlikely 
to contribute significantly to washout effects, the considerable increases in peak inspiration turbulence 
intensity may assist in diluting any CO2 retained in the anatomic dead space. It is also possible that in 
other regions of the upper airway the use of NHF therapy produces much greater increases in 





9 Carbon Dioxide Washout of Anatomic Dead Space 
Carbon dioxide is constantly produced within human body cells as a waste product of cellular 
respiration. It is continuously delivered to the lungs for expulsion in the venous blood, or 
deoxygenated blood, where it passes through the pulmonary capillaries which cover the alveoli. 
Diffusion of the CO2 from the blood into the alveoli is driven by the pressure gradient across the 
interstitial respiratory membrane, such that CO2 diffuses into the lungs to attain an equilibrium 
concentration. When at rest, the deoxygenated blood entering the pulmonary capillaries has a CO2 
partial pressure of 45 mmHg and an O2 partial pressure of 40 mmHg (Tortora and Derrickson, 2006). 
Within the alveoli the partial pressures of CO2 and O2 respectively are 40 and 105 mmHg (Tortora 
and Derrickson, 2006). Following gas exchange, the partial pressures within the oxygenated blood 
leaving the pulmonary capillaries have changed to 40 mmHg of CO2 and 100 mmHg of O2 (Tortora 
and Derrickson, 2006). This results in a CO2 concentration of 5.2% in the lungs. For an average 
human adult the diffusion rate of CO2 into the lungs occurs at 200 ml/min (Widmaier et al., 2011). 
This is equal to the diffusion rate of O2 into the pulmonary blood when at rest (Tortora and 
Derrickson, 2006).  
For those subjects suffering from respiratory distress, attaining the level of respiratory ventilation 
required to maintain this equilibrium of concentrations is difficult and can result in hypoxemia, low 
oxygen levels in the arterial blood. These patients require some form of ventilation therapy, such as 
Optiflow™ NHF, to reduce the stress on the body and achieve a healthy level of blood oxygenation. 
Optiflow™ NHF therapy has been shown to improve the blood oxygenation levels of patients 
suffering from mild to moderate respiratory distress as effectively as the more established full face 
mask oxygen therapy. Moreover, use of Optiflow™ NHF therapy has a greater level of patient 
compliance to the therapy regime. Though it has been proven to improve blood oxygen saturation, the 
mechanisms by which this is achieved are still unproven. 
The main proposed mechanism, investigated by the experiments laid out in this chapter, is the CO2 
washout of the anatomic dead space. If regions of the conducting airways are continuously flushed 
with fresh air by NHF therapy, then the ratio of alveolar gas to air that is contained in the conducting 
airways over the course of a breath cycle is reduced. This equates to a reduction in the average 
concentration of CO2 and an increase in the average concentration of O2 maintained in the airway over 
the breath cycle. Subsequently, the higher concentration of O2 residing in the conducting airways at 
the onset of inspiration will increase the partial pressure of O2 in the lungs thus improving the rate of 
gas exchange across the alveolar wall. Similarly the lower concentration of CO2 in the conducting 
airways results in a decrease of the partial pressure of CO2 in the lungs, increasing the diffusion rate 
of CO2 into the lungs. 
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The reduction of the CO2 concentration and the resulting increase in O2 concentration within the 
conducting airways can also be seen as an apparent reduction in the anatomic dead space. As some 
volume of alveolar gases are flushed out and replaced with NHF gases, the fresh air is apparently 
closer to the lungs and thus the anatomic dead space is decreased. The two in vitro experimental 
methods, Experimental Methods Version One and Two, employed to determine the CO2 dead space 
washout and the influence of Optiflow™ NHF are described in the following sections. For both 
methods air was employed as the NHF therapy gas as measurement of CO2 washout was the major 
experimental focus and the use of O2 or an air-oxygen mix could not reasonably be thought to have a 
significant influence on the CO2 concentrations observed. Performing these experimental methods in 
vitro allowed for much greater variable control and prevented certain complications associated with in 
vivo measurements such as the physical inaccessibility of airway regions and uncontrollable breathing 
patterns. 
9.1 Experimental Method Version One 
The first experimental method developed to examine the occurrence of anatomic dead space washout 
focused on measuring a CO2 concentration rate of decay. As previously stated this experimental 
method was not intended to be true to the physiological process of respiration. Rather, this was an 
initial means of determining the relative efficacy of Optiflow™ NHF therapy at reducing the CO2 
level within the experimental system as opposed to operating the system as a naturally breathing 
adult. Two variations of the system setup were trialled for the CO2 concentration decay, defined and 
described below as Set-up One and Two. 
As these experiments were carried out early in the research the experimental respiratory system was in 
one of its early forms as described in the Chapter 5 with a larger than average FRC volume, some of 
which was contained within the connections between the pump and the model. Similarly, the breath 
flow waves used to drive the pump were the initial patterns derived directly from live subject 
measurements. These breath waves are described in detail in Chapter 6. Only two breathing cases 
were examined, natural breathing and a single, midrange NHF therapy flow rate of 30 LPM for testing 
NHF efficacy. For the 30 LPM NHF therapy case the pump was driven by the Fourier series derived 
from measurements on the live subject experiencing the same level of NHF therapy. For the 
experiment with no Optiflow™ NHF therapy in use the original natural breathing flow wave, tidal 
volume of 799 ml and breathing period of 5.08 seconds, was employed to drive the pump. To test the 
fidelity of the experimental method the natural breathing test performed with Set-up Two was 
repeated a total of six times for comparison. 
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9.1.1 CO2 Concentration Decay Experimental Procedure 
Set-up One 
To prepare the experiment using the first setup the pump piston was retracted to give the largest 
possible volume of 5.84 litres within the entire experimental system. The pump and the step down 
connections were isolated from the later connections and airway model as illustrated in Figure 63. The 
volume was then sealed off and the ball valve from the CO2 feed system into the pump was opened. 
Initially the line from the CO2 rotameter to the pump ball valve was broken so that any CO2 feed 
would not pass into the pump while stabilising the CO2 flow. The CO2 feed was adjusted until a 
desired flow rate was achieved, then allowed to stabilise. The required volume of CO2 was then 
introduced by reconnecting the feed line, allowing CO2 flow into the pump for a specified time period 
followed by closing off of the ball valve. This method allowed for introduction of CO2 to give a 
concentration of close to 2000 ppm (0.2 % V/V), the limit of the sensor used for the experiments. Set 
up of the system was then completed by unsealing the connections to the pump outlet and reattaching 
the rest of the experimental system. 
Figure 63: Set-up One schematic illustrating by the dashed red line the point of isolation of the pump and 
step down connections. 
For measurements in which Optiflow™ NHF therapy was applied to the model, the cannula was set 
up on the model and the NHF flow rate established before the pump was reconnected to the rest of the 
system to avoid any delays post reconnection. 
Set-up Two 
The second experimental setup procedure was almost identical to that of the first, with all the steps 
from Set-up One carried out except for placement of the cannula on the model. Once CO2 had been 
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introduced to the pump and the system components all reconnected, one further step was taken. The 
piston was advanced to provide the smallest possible volume within the system, at 3.58 litres, while 
simultaneously flushing the downstream connections and components with the increased CO2 
concentration air. To prepare for the measurements with Optiflow™ NHF therapy the cannula flow 
rate was established prior to placing the cannula on the model, which was carried out only once the 
above steps were complete. 
9.1.2 Data Acquisition 
Experiments were begun immediately after all preparation steps had been finalised to prevent 
unwanted gas mixing by diffusion. Data acquisition from the gas sensor and flow meter were initiated 
at a sampling frequency of 100 Hz followed by starting of the pump. The system was allowed to run 
until the CO2 concentration decay had plateaued and a level of less than 600 ppm (0.06 %V/V) was 
achieved. The concentration of CO2 in the earth’s atmosphere is approximately 400 ppm (Wayman et 
al., 2013) however this level can be much higher in inhabited buildings, thus the lower limit of 600 
ppm was chosen as it was the lowest level which was consistently attainable in the experimental area. 
9.1.3 Data Processing 
Initially it was thought that the measured data from different experimental runs could be directly 
compared to one another. However it was soon obvious that due to the very low level of CO2 
introduced into the system, as restricted by the sensor range, there was significant variation in the 
concentration of CO2 at the commencement of each individual experiment. The poor repeatability of 
the initial CO2 concentration prompted a change in the method of data processing. 
All concentration data was converted from units of ppm to %V/V for consistency with the later 
Experimental Method Version Two experiments. A reference level of initial CO2 was then set at 0.08 
%V/V at which point analysis of data would begin. The time taken, in seconds, for the CO2 
concentration to reach the second reference level of 0.06 %V/V was extracted from each data set. A 
theoretical time to attain the same reduction in concentration was also found assuming perfect mixing 
of inspired air with the rest of the system volume. This was calculated iteratively using equation [ 7 ] 
with variables Vs, the total system volume; Vt, the tidal volume; Ci, the average CO2 concentration in 
the system at the beginning of breath cycle i, and Ca, the concentration of CO2 in the room air. The 
equation states that during each breath cycle a portion of the total system volume, the tidal volume, is 
expelled via expiration and replaced with room air on inspiration. By assuming perfect mixing, the 
instantaneous CO2 concentration within the system at the end of a breath cycle is therefore a weighted 
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average of the initial system concentration and room air concentration based on their relative volumes. 











  [ 7 ] 
 
Figure 64: Example of the outputs from the iterative calculation using Equation [ 7 ] to find the number 
of theoretical breath cycles for a 0.08 to 0.06 %V/V CO2 decay when assuming perfect mixing. 
This calculation was carried out for all four experiment scenarios performed using Set-up One and 
Set-Up Two. When calculating the theoretical time for the two experiments in which NHF therapy 
was used at a flow rate of 30 LPM, the occurrence of dead space washout was ignored. Thus the only 
influencing factors providing difference to the four scenarios were the variation in pump volume 
between Set-ups One and Two, and the period of the breath cycle between natural breathing and 
breathing with the 30 LPM NHF therapy.  
9.1.4 Results and Discussions 
From the theoretical calculations it was found that only 8 breath cycles would be required to attain the 
reduction from 0.08 to 0.06 %V/V CO2 in Set-up One when assuming perfect mixing. This was the 
case for both scenarios of natural breathing and breathing with 30 LPM NHF therapy, as the 
difference in the tidal volume between the two was small at only 15 ml. Despite requiring the same 
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number of cycles, the decay time is slightly higher for the 30 LPM NHF therapy scenario as the breath 
period is longer than that of natural breathing. For Set-up Two the theoretical decay times were 
reduced to a mere 5 breath cycles for both breathing with 30 LPM NHF and natural breathing due to 
the reduction in the system volume. These results and the times are listed in Table 5 alongside the 
results extracted from the experimental data. 
It was immediately apparent from the results of these experiments that metering a preset volume of 
CO2 into the pump volume could not be repeated accurately. Consequently it was necessary to set an 
upper limit attained by all experiments from which the time analysis could be started. Figure 65 shows 
the full time series of the four decay experiments, with all reaching levels above 0.08 %V/V upper 
limit. 
Figure 65: Full time series of CO2 concentration decay results from experimental Set-ups One and Two. 
Figure 66 shows all experiments with results beginning at the upper limit of 0.08 %V/V. In this plot 
the most significant observable difference is between the two setups used, with the Set-up Two results 
decaying to the lower limit much faster than the two datasets obtained using Set-up One. For Set-up 
One alone the use of NHF therapy at 30 LPM accelerated the rate of decay to a small extent when 
compared to the natural breathing case. Conversely, in Set-up Two the use of NHF therapy decreased 
the rate of CO2 decay when compared to the natural breathing result. 
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Figure 66: CO2 decay curves of both Set-up One and Two beginning at upper limit of 0.08 %V/V. 
The times taken for each experiment to decay from 0.08 to 0.06 %V/V CO2 were extracted and are 
given in Table 5. Comparisons between the theoretical and experimental decay times show extreme 
differences with experimental times an order of magnitude greater than those calculated. It was not 
expected that perfect mixing would occur within the system and these large disparities show 
definitively that this assumption is inadequate.  
Table 5: Theoretical and experimental CO2 concentration decay results. 
 Set-up One Set-up Two 
 0 LPM NHF 30 LPM NHF 0 LPM NHF 30 LPM NHF 
Breath Cycle Period 5.08 s 6.63 s 5.08 s 6.63 s 
Tidal Volume 0.799 l 0.814 l 0.799 l 0.814 l 
Theoretical Number of Cycles for Decay 8 8 5 5 
Actual Number of Cycles for Decay 76.43 53.57 42.22 39.84 
Theoretical Decay Time 40.64 s 53.04 s 25.40 s 33.15 s 
Actual Decay Time  388.26 s 355.17 s 214.46 s 264.17 s 
Actual Total Volume Exchanged 59.20 l 43.96 l 33.73 l 32.56 l 
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Comparison of the results from Set-up One show that the introduction of NHF therapy did reduce the 
time for CO2 decay from 388.26 seconds for natural breathing to 355.17 seconds. The total volume 
exchanged to achieve this decay was also reduced by 15.25 litres. Set-up Two results also show a 
reduction in the total volume exchanged with the introduction of NHF; however, the decay time was 
faster for natural breathing. In spite of a lesser number of cycles and thus the lower volume exchanged 
with the introduction of 30 LPM NHF, the much shorter breath period of natural breathing produced a 
faster decay in this setup. As other contributing variables such as tidal volume differences were 
present in these experiments, the difference in the decay rates are most likely cumulative and not 
directly attributable to the introduction of NHF flow alone.  
By comparing the results from the analogous experiments of Set-ups One and Two it is obvious that 
the system volume has a large influence on the rate of the CO2 decay. The reduced system volume of 
Set-up Two resulted in much faster decay times of 214.46 seconds as opposed to 388.26 seconds and 
264.17 seconds as opposed to 355.17 seconds for the natural breathing and 30 LPM NHF scenarios 
respectively. However there is no consistent reduction attributable to the use of NHF therapy in these 
four experiments.  
Six repetitions of the Set-up Two natural breathing experiment were carried out to determine 
experimental repeatability, the results of which are plotted in Figure 67 with data all beginning at 0.08 
%V/V. The figure shows that there are significant differences in the decay curves of the six 
experiments resulting in a wide variation of decay times. The decay times from the analysed curves 
are laid out in Table 6. 
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Figure 67: Repeatability tests of CO2 decay during natural breathing using Set-up Two. 
Table 6: Results of CO2 decay repeatability experiments. 
These repeatability results give an average decay time of 184.87 seconds with a standard deviation of 
23.53 seconds for natural breathing with experimental Set-up Two. With the standard deviation this 
high, equal to 12.7% of the average value, the repeatability of these experiments is poor. It can also be 
seen in Figure 65 to Figure 67 that there are noticeable step changes in the CO2 concentration curves. 
These step changes result from the low response rate of the sensor which was unable to accurately 
capture the decay. As a consequence of these issues, the non-physiological experimental system 
volume and the non-physiological introduction of CO2 as a single fixed volume as opposed to a 
continuous flow, these results were concluded to be of little practical use. Subsequently Experimental 
Method Version One was not pursued further in favour of developing and using the physiologically 
representative Experimental Method Version Two. 
 One Two Three Four Five Six 
Actual Number of Cycles 42.22 42.16 32.62 34.36 31.93 35.06 
Actual Decay Time  214.46 s 214.18 s 165.69 s 174.53 s 162.21 s 178.13 s 
Total Actual Volume Exchanged 33.73 l 33.69 l 26.06 l 27.45 l 25.51 l 28.02 l 
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9.2 Experimental Method Version Two 
The second experimental method undertaken to investigate anatomic dead space washout was 
designed to replicate an average adult respiratory system and measure the time-averaged 
concentration of CO2 at a single reference point within the conducting airways. This method would be 
capable of giving a clearer picture of what occurs in live subjects and how Optiflow™ NHF therapy 
influences the concentrations of CO2 in the anatomic dead space. O2 concentrations were also 
measured simultaneously for additional information. This method was used to determine whether 
Optiflow™ NHF therapy provided dead space washout and to what degree it did so for various levels 
of NHF therapy. Following this, further experiments were carried out to investigate how the efficacy 
of the therapy was itself affected by variation in the upper airway geometry variation. 
The efficacy of Optiflow™ NHF therapy was the first experiment set carried out and the method used 
became the basis for all following tests in which the upper airway geometry variation was 
investigated. Measurements of the CO2 and O2 concentrations during natural breathing with the 
standard airway 06B model were carried out on each day of testing as a measure of experimental 
repeatability. The introduction of CO2 into the system was found to be a likely source of error 
introduction due to the manual control of pressure and flow rate as well as the conversions required to 
account for the disparity between rotameter calibration and working fluid. Repeatability tests were 
subsequently considered an appropriate action to mitigate the risk of error introduction. The 
experimental system employed for these tests was as described in Chapter 5. The pump, set up to 
contain an average adult FRC volume of 2400 ml, was driven by the average adult breathing pattern 
with the 450 ml tidal volume and breathing rate of 14 breaths per minute for all Experimental Method 
Version Two CO2 washout experiments.  
9.2.1 Data Processing 
Though the experimental methods varied slightly the process of data analysis remained constant for 
all results obtained, and will therefore be explained once here. As the CO2 introduction into the system 
was continuous and constant throughout each ten minute experiment every dataset was checked to 
ensure that the overall CO2 concentration trend was constant to confirm the system was in equilibrium 
throughout data capture. If a positive or negative trend was seen to be caused by a small region of data 
at the start of the set, the dataset would be cropped to leave the constant majority. However if the non-
constant trend pervaded the entire dataset, experiments were repeated. As the response times of the 
new CO2 and O2 sensors were still in excess of the breath cycle period, direct comparison of the 
transient concentrations across a single cycle was impractical. Instead a temporal average was found 
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for each set of data providing an average CO2 concentration at the measurement position for the 
particular state examined. The O2 concentration data was processed using the same method. 
9.2.2 Efficacy of Anatomic Dead Space Washout with Optiflow™ NHF Therapy 
The first experiment undertaken was to determine the efficacy of anatomic dead space washout with 
the use of Optiflow™ NHF therapy and how the level of dead space washout was affected by the flow 
rate of NHF therapy employed. This set of experiments then became the basis of the further 
experiments performed for the investigation of upper airway geometry influences on therapy efficacy. 
Experimental Procedure 
To determine the efficacy of anatomic dead space washout when using Optiflow™ NHF therapy the 
following protocol was designed. An illustration of the experimental system employed is provided in 
Figure 68. As laid out in Chapter 5, calculations had to be carried out in order to determine the 
rotameter flow rate required to replicate the rate of CO2 diffusion into the lungs. For an average 
person with an alveolar ventilation of 4000 ml/min, this rate is known to be approximately 
200ml/min. Due to the calibration of the rotameter, adjustments had to be first be made for the 
calibration error, temperature dependent buoyancy of the CO2 and back pressure of the compressed 
CO2 source so that the flow rate could be set correctly. After calculation of the rotameter flow rate, the 
volume of the pump was set to the average adult FRC volume of 2400 ml by adjusting the piston 
position. The pump was started so that it was providing the oscillatory flows of an average adult, with 
a tidal volume of 450 ml and breathing rate of 14 breaths per minute. Starting the pump first 
prevented the CO2 concentration from rising above the level found within an average pair of lungs 
while initiating and stabilising the CO2 feed. To set the CO2 feed rate the ball valve into the pump was 
opened, the gas cylinder turned on and the back pressure set to 50 PSIG. The flow rate through the 
rotameter was carefully metered to the calculated value with particular attention paid to maintaining 
the correct back pressure. Once set the flow rate, back pressure and pump CO2 concentration were 
given at least five minutes to settle to equilibrium. The data acquisition system was set to log the gas 
sensor outputs of both the CO2 and the O2 concentrations at a rate of 100 Hz for ten minutes for each 
test. 
A control experiment was carried out first with the system replicating a naturally breathing adult, with 
no cannula in place on the standard testing model airway 06B. Results from this test provided the 
baseline expectations for the gas concentrations. Experiments were then conducted with Optiflow™ 
NHF therapy applied to the model. NHF flow rates of 10 to 80 LPM were tested at intervals of 10 
LPM to provide a map of the efficacy of CO2 dead space washout as a function of NHF flow rate. 
100 
 
These tests at natural breathing and breathing with NHF flow rates from 10 to 80 LPM were then 
repeated on a further three separate days to determine the experimental repeatability. 
Figure 68: Experimental respiratory system schematic for Experimental Method Version Two. 
Results and Discussions 
For the first iteration of this experiment the CO2 concentration outside the lung pump settled to an 
average value over many breath cycles of 4.85 %V/V during the replication of natural breathing. 
Introduction of Optiflow™ NHF therapy induced a reduction in this average concentration with 
higher flow rates providing lower average CO2 concentrations. At the highest NHF flow rate 
employed of 80 LPM an average CO2 concentration was measured as 3.84 %V/V. Further repetitions 
of the same experiment on three separate occasions showed a close agreement between the average 
CO2 concentrations measured during natural breathing. Larger differences were seen between average 
concentrations observed during administration of Optiflow™ NHF therapy; however none of these 
exceeded 4.9% of the lowest measured average. The plot of Figure 69 shows the results from all four 
repetitions of the experiment, with horizontal error bars indicating the level of variation in the NHF 
flow rate supplied due to air supply instability.  
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Figure 69: Time-averaged CO2 concentrations during natural breathing and breathing with Optiflow™ 
NHF flow rates from 10 to 80 LPM showing experimental repeatability over four separate days of testing. 
The results from these repeated experiments were used to determine a mean value for the average CO2 
concentration at natural breathing and for each flow rate of Optiflow™ NHF therapy. The variation 
observed in the concentrations over the four days of testing for the same breathing condition, natural 
breathing and for each specific level of NHF therapy, were then used to define an error for each. This 
was specified as two standard deviations of the repeatability results either side of the mean, with the 
standard deviation, σ, calculated using the formula of Equation [ 8 ] where x is the measured CO2 
concentration and   the mean CO2 concentration. Figure 70 provides a plot of these mean CO2 
concentrations with the associated errors derived from the repeatability experiments. The trend of the 
mean CO2 concentrations can be closely approximated by a second order polynomial within the range 
of breathing conditions tested. The second order polynomial fit, with an R-squared value of 0.99, is 
also plotted with the data in Figure 70. 
    
 
   
       
 
 
   




Figure 70: Mean time-averaged CO2 concentrations observed during natural breathing and breathing 
with Optiflow™ NHF flow rates from 10 to 80 LPM. 
The mean values from the repeated experiments give a time-averaged CO2 concentration of 4.88 ± 
0.07 %V/V during the natural breathing condition. Breathing with only the lowest Optiflow™ NHF 
therapy level of 10 LPM resulted in a 0.28 %V/V reduction to an average CO2 concentration of 4.60 ± 
0.05 %V/V. When breathing with the highest flow rate of Optiflow™ NHF therapy this level had 
dropped to a mean CO2 concentration of 3.81 ± 0.11 %V/V. Optiflow™ NHF therapy flows of 10 to 
30 LPM provided significant reductions in the CO2 concentration, after which the decline began to 
slow with increasing NHF flow rates. With only 30 LPM NHF therapy there is reduction of 0.76 
%V/V in the CO2 concentration from that observed during natural breathing. By increasing the NHF 
flow rate to 80 LPM only another 0.31 %V/V reduction is gained, thus the most significant reductions 
are seen within the first 30 LPM of therapy. This is an interesting result when taking into 
consideration the static pressure measurements which showed 30 LPM to be the lowest level of 
Optiflow™ NHF therapy for which the inspiratory resistance of the upper airway was completely 
compensated for by the NHF flow provided. As increasing the NHF flow rate further induces greater 
rises in the resistance to expiration while yielding more modest reductions in the concentration of 
CO2, it is likely that some NHF flow rate close to 30 LPM would be optimal if this were a live 
subject.  
The repeatability results of the average O2 concentration show a much greater spread at each 
breathing condition as shown in Figure 71. As for the average CO2 concentration plot the horizontal 
error bars show the level of variation in the NHF flow rate supplied due to instability in the air supply.  
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Figure 71: Time-averaged O2 concentrations during natural breathing and breathing with Optiflow™ 
NHF flow rates from 10 to 80 LPM showing experimental repeatability over four separate days of testing. 
From these repeatability results a mean O2 concentration was calculated for each breathing condition 
along with an associated repeatability error once again defined as two times the standard deviation of 
the results. The mean O2 concentration curve is given in Figure 72 which shows the results have very 
low repeatability. As the NHF therapy supplies ambient air, of which 70 %V/V is nitrogen and only 
21 %V/V is oxygen, only a fraction of the volume of CO2 flushed from the airway is replaced with 
oxygen. Therefore any increase in the magnitude of O2 concentration observed will only be a fraction 
of the observed decrease in CO2 concentration. Because of this, the high variation seen in the O2 
concentration results is even more significant, with some error bars spanning almost the entire range 
of observed time-averaged O2 concentrations. As a result of this O2 concentration results from further 
experiments were disregarded as unreliable. 
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Figure 72: Mean time-averaged O2 concentrations during natural breathing and breathing with the 
implementation of various flow rates of Optiflow™ NHF therapy with vertical error bars illustrating low 
repeatability of results. 
The results of these experiments showed that introduction of Optiflow™ NHF therapy results in a 
significant reduction in the concentration of CO2 observed. Higher flow rates of NHF therapy 
produced lower concentrations of CO2, however the relationship was not linear and the rate of CO2 
reduction decelerates with increasing NHF flow rate. The experiments showed a good level of CO2 
measurement repeatability across the four repetitions with close agreement at natural breathing and 
differences not exceeding 5% of the lowest measured value. Conversely, O2 concentration 
measurement repeatability was found to be very low and as a result further O2 measurements were 
disregarded. 
9.2.3 Influence of Upper Airway Variation 
Experimental Procedure 
As the geometry of the human airway is unique for every individual; with variation in airway patency, 
internal volume and geometrical features; the efficacy of Optiflow™ NHF therapy may depend upon 
the user. To gain insight into the variation in Optiflow™ NHF therapy efficacy caused by the upper 
airway anatomic differences between subjects the experiment described in the previous section was 
carried out using a further four unique upper airway models, giving a total of five airways tested. 
These upper airway models were the five unique geometries described in Chapter 4. By performing 
this NHF flow rate experiment on five different airway models the dependence of the average CO2 
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concentration on the rate of NHF therapy could be determined for each individual model. 
Subsequently comparisons of this dependency could be made to gain understanding into how the 
efficacy of the therapy may vary between subjects. 
Each airway model was set up with the experimental respiratory system in the same manner as the 
standard upper airway model as explained in Chapter 5 and illustrated by Figure 68. A large size 
Optiflow™ cannula was fitted to each model for all tests requiring Optiflow™ NHF therapy. Images 
showing the fit of the cannula on airway 16 in comparison to the fit on the standard airway 06B model 
are provided in Figure 73 from which it is notable that the cannula prongs on the airway 16 model are 
significantly deformed by the size and shape of the nares. Medium and small cannula were tried on 
the airway 16 model in an attempt to provide a better fit; however, both were worse fitting than the 
original large cannula resulting in the final use of the large cannula. 
  
Figure 73: Comparison of large size Optiflow™ cannula fit on airway 06B model (left) and airway 16 
model (right) showing ill-fitting nature of cannula on the airway 16 model. 
Results and Discussions 
A significant level of variation was seen in the average CO2 concentrations observed during natural 
breathing across the five airway models. The variation in the CO2 concentrations observed increased 
with the introduction of 10 LPM Optiflow™ NHF therapy and continued to increase with increasing 
NHF flow rates. The results obtained for each unique upper airway model are plotted together in 
Figure 74, with flow rate errors determined from the reliability of the air supply during each test and 
concentration errors taken to be equal to that determined from the repeatability experiments 
performed previously. Concentration error bars have been plotted only on the highest and lowest 
values to preserve clarity. This plot shows that the variation seen between the different models for the 
same testing conditions are significantly greater than the repeatability error and can therefore be 
attributed to airway model differences. Despite the significant differences in the efficacy of the 
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Optiflow™ NHF therapy observed between the airway models, a significant level of CO2 washout was 
achieved for each with increasing levels of therapy providing improved reductions in the average CO2 
concentration. 
Figure 74: Average CO2 concentrations during natural breathing and breathing with Optiflow™ NHF 
therapy flow rates of 10 to 80 LPM for each of the five unique upper airway models showing significant 
variation. 
As variation was seen in the time-averaged CO2 concentrations and therapy efficacy across the 
different airway models an investigation of the physical differences was undertaken to determine if 
the causes of these variations could be simply explained. A number of the physical differences in the 
airway models were able to be identified and measured by employing the mesh analysis software 
packages MeshLab and netfabb
®
 Basic. The first of these was the internal upper airway volume. As 
all other sections of the experimental setup remained constant throughout the tests, the variation in the 
airway model volumes would cause slight differences in the dead space and overall system volume. 
The total volume of each airway model was measured by editing each airway mesh in MeshLab such 
that the trachea exit and the nares were capped to close the internal upper airway volume. The volume 
of each was then attained using the netfabb Basic analysis tool. The surface area of the internal airway 
was also extracted from these meshes prior to capping the nares and trachea exit. The results of these 




Table 7: The internal volumes and surface areas of the five unique upper airway models. 
Both internal airway volume and surface area were plotted against the average CO2 concentrations 
observed during natural breathing and breathing with two representative Optiflow™ NHF therapy 
flow rates to establish if there were any prevailing relationships. The plot of average CO2 
concentration as a function of upper airway internal volume is given in Figure 75 while Figure 76 
gives a plot of the same CO2 concentrations as a function of the upper airway internal surface area. In 
both figures the natural breathing data point for each airway is labelled, with all three vertically 
aligned points belonging to the same airway. In Figure 76 the CO2 concentrations for airways 16 and 
09 fall on almost the same vertical line as the upper airway internal surface areas are very similar, 
however they are distinguishable as airway 09 has the greater CO2 concentrations for all three 
experiment conditions. These two plots show no discernible relationship between the CO2 
concentration and either the upper airway internal volume or surface area. Microsoft Excel was used 
to fit linear, power and second and third order polynomial curves to the data within each plot and R-
squared values were used to determine the accuracy of each fit. No curve fit provided an R-squared 
value in excess of 0.65; therefore none were considered a true representation of the data. 
Figure 75: Average CO2 concentrations observed as a function of the upper airway model internal 
volumes for natural breathing and two representative flow rates of Optiflow™ NHF therapy. 
Upper Airway Airway 06B Airway 07B Airway 09 Airway 10 Airway 16 
Volume [cm
3
] 53.84 60.16 48.27 57.57 43.70 
Surface Area [cm
2
] 307.91 330.33 281.88 304.70 281.73 
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Figure 76: Average CO2 concentrations as a function of the upper airway model internal surface area for 
natural breathing and two representative flow rates of Optiflow™ NHF therapy. 
As the combined cross-sectional area of the nasal valves is the smallest within the nasal passage they 
were considered another point of interest and possible contributor to the average CO2 concentration 
differences observed across the airway models. These cross sections were subsequently extracted 
from each airway and measured using netfabb Basic. This was achieved by estimating the central flow 
path through each nasal valve and inserting a plane normal to the flow path to extract the minimum 
cross section which could then be measured. It was further decided that the small cross-sections 
formed at the velopharynx and larynx contractions would similarly be of interest, therefore they were 
also extracted using the same process. Additionally, the overall maximum cross-sectional area from 
each airway nasopharynx was also captured and measured and the overall upper airway minimum was 
extracted from the nasal valve, velopharynx and larynx values. The results of these measurements are 
provided in Table 8. 
Table 8: Measured cross-sectional areas of interest for the five airway models. 
Cross-Sectional Area [cm
2
] Airway 06B Airway 07B Airway 09 Airway 10 Airway 16 
Nasal Valve (Total) 2.22 1.84 1.29 0.98 1.51 
Velopharynx 0.91 1.08 0.64 0.94 0.81 
Larynx 0.79 0.77 0.71 1.11 0.42 
Minimum 0.79 0.77 0.64 0.94 0.81 
Maximum 4.30 4.76 4.18 4.57 4.97 
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A plot of the average CO2 concentration as a function of cross-sectional area was then created for 
each of the five measurement sets of Table 8 to determine if any simple relationships could be 
extracted. These were prepared in the same manner as the volume and surface area measurements 
with natural breathing and breathing with two representative NHF flow rates of 40 and 80 LPM. The 
plots for each of these are given in Figure 77 to Figure 81. The results of these plots show that cross-
sectional area of the larynx, given in Figure 79, provides the most reasonable linear fit to the CO2 
concentration during natural breathing with an R-squared value of 0.92. The minimum cross-sectional 
area, shown in Figure 80, also provides a reasonable linear fit of to the natural breathing data with a 
0.85 R-squared value. The other three cross-sectional area variables of Table 8 show no close relation 
to the natural breathing CO2 concentration observed.  
From both the pressure and turbulence intensity measurements, as well as previous CFD 
investigations, it is known that on expiration the larynx projects a jet into the pharynx. It is perhaps 
possible that by having a smaller cross-section at the larynx the expiration jet of CO2 rich air which 
enters the pharynx has a higher velocity and is subject to less mixing with the ambient air occupying 
the pharynx volume at the conclusion of inspiration. In this case the expired air exiting the nares 
would have a higher CO2 concentration; therefore, for the same CO2 production rate at the lungs, less 
CO2 would reside in the upper airway at the start of the subsequent inspiration. This would lead to an 
overall lower average CO2 concentration being observed. 
 
Figure 77: Average CO2 concentrations as a function of the total minimum cross-sectional area of the 




Figure 78: Average CO2 concentrations as a function of the minimum cross-sectional area of the 
velopharynx for natural breathing and breathing with two representative flow rates of Optiflow™ NHF 
therapy. 
 
Figure 79: Average CO2 concentrations observed exterior to the lung pump during natural breathing and 
breathing with two representative flow rates of Optiflow™ NHF therapy as a function of the minimum 




Figure 80: Average CO2 concentrations as a function of the overall minimum cross-sectional area of the 
upper airway for natural breathing and breathing with two representative flow rates of Optiflow™ NHF 
therapy. 
 
Figure 81: Average CO2 concentrations as a function of the overall maximum cross-sectional area of the 






Though a reasonable relationship is seen between the larynx cross-sectional area and the average CO2 
concentration during natural breathing, this does not extend to the concentrations observed when 
Optiflow™ NHF therapy was in use. With increasing NHF flow rates the linear fit becomes 
increasingly less accurate with the worst fit occurring at 40 LPM, after which point the fit improves 
again to a maximum R-squared value of 0.81. This is also the case for all of the other four plots 
derived from the Table 8 measurements with Optiflow™ NHF therapy results producing worse fits 
than natural breathing. This implies that though there may be a simple geometrical feature which 
governs the average CO2 concentration during natural breathing, the introduction of NHF therapy 
disturbs this relation. 
The geometrical form of the upper airway is unique to each airway model and has a high level of 
complexity. As the differences seen in the CO2 concentration measurements can only be attributed to 
the variation in the airway models it was thought that a relationship may be found from a 
characteristic length. This was defined as the ratio of airway volume to surface area, against which the 
CO2 concentrations were plotted in Figure 82. Setting a linear fit to the natural breathing data 
provided a reasonable fit with a 0.84 R-squared value. This is not as strong as the fit found when 
plotting the CO2 concentrations against the minimum cross-sectional areas at the larynx and only 
slightly worse than the linear fit for upper airway minimum cross-sectional area. However, when 
compared to the fits created when plotting the CO2 concentrations against the upper airway volumes 
or surface areas alone, this fit which combines both factors is significantly more accurate. 
Figure 82: Average CO2 concentrations as a function of the ratio of upper airway volume to surface area 
for natural breathing and breathing with two representative flow rates of Optiflow™ NHF therapy. 
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Another measure was developed in an attempt to define the uniformity and patency of each upper 
airway by using the ratio of minimum to maximum cross-sectional areas. The average CO2 
concentrations were then once again plotted against this ratio to determine if a relationship could be 
drawn between them. Figure 83 shows this plot that, for natural breathing, provides a reasonable 
linear relationship to the CO2 concentration with an R-squared value of 0.85. This fit is therefore no 
better than that determined from the larynx cross-sectional area data and is in fact as good as the fit 
provided when plotting the CO2 concentration against the minimum upper airway cross-sectional area 
alone. As for all previous plots of CO2 concentration as a function of airway model measurements it 
was found that with the introduction of Optiflow™ NHF therapy the linear fit became less suitable. 
Figure 83: Average CO2 concentrations as a function of the ratio of minimum to maximum upper airway 
cross-sectional areas for natural breathing and breathing with two representative flow rates of 
Optiflow™ NHF therapy. 
By plotting the CO2 concentration as a function of easily identifiable large-scale and local upper 
airway measurements some possible relationships have been uncovered for the case of natural 
breathing. The minimum cross-sectional area of the larynx provides the strongest linear fit to the data, 
while the overall minimum cross-sectional area of the upper airway and also the ratio of upper airway 
volume to surface area both provide reasonable linear trends. The upper airway volume to surface 
area is in particular of interest as the individual volume and surface area measurements showed no 
prevailing relation to the CO2 concentration results until combined. Due to the small sample size it is 




As a final investigation each airway was visually inspected in netfabb
®
 Basic for any obvious 
geometrical differences which may explain the differences seen in the CO2 concentrations. Initially 
airways were examined and compared as a whole to little effect. Subsequently the nasal cavities of 
each airway were broken down into sections perpendicular to the approximate central flow path to 
observe and compare the complexity of the meatuses. Figure 84 provides the three central nasal cavity 
cross sections taken from each airway with the positioning of the cutting planes illustrated in the left 
hand images of the airways. Though the airways presented many geometrical differences, as 
demonstrated by Figure 84, no pattern of differences which would explain the differences in CO2 
concentration could be elucidated. 
This set of experiments determined that the individuality of the upper airway has a significant effect 
on the average concentration of CO2 seen during both natural breathing and breathing with 
Optiflow™ NHF therapy when all other experimental parameters are kept constant. Some 
relationships were found between the average CO2 concentration observed during natural breathing 
and the minimum cross-sectional area of the larynx, the overall minimum upper airway cross-
sectional area and finally the ratio of upper airway volume to surface area. A greater number of 
unique airway geometries are necessary to determine the strength of these relationships. These trends 
did not extend to the cases in which Optiflow™ NHF therapy was in use. This combined with the 
impracticality of performing the same measurements on live patients receiving Optiflow™ NHF 
therapy means that there is limited use for this information for the cannula product design process or 
development of clinical protocol. The findings are however relevant as they show the use of 
Optiflow™ NHF therapy induces a reduction in the average CO2 concentration observed during 





   
 
   
 
   
 
   
 
   
 
Figure 84: Nasal cavity cross sections of airways 06B, 07B, 09, 10 and 16 in order from top to bottom. The 
left hand column shows a side view of each airway with analogous cutting planes marked by green, blue 




CO2 washout of the anatomic dead space with the use of Optiflow™ NHF therapy was investigated 
with the use of two experimental methods. The first, Experimental Method Version One, found that 
an initial concentration of CO2 introduced to the lung pump decayed to a reference value of 600 ppm 
for a fewer number of breath cycles when breathing with 30 LPM NHF flow in comparison to decay 
during natural breathing. However due to low repeatability of the experiments this method was 
abandoned.  
Experimental Method Version Two was designed to replicate the physiological process of continuous 
CO2 diffusion into the lungs during breathing with CO2 measurement just exterior to the lung volume. 
With this method time-averaged CO2 concentrations were able to be determined so that the efficacy of 
Optiflow™ NHF therapy could be assessed for a number of different airway geometries. At natural 
breathing a mean time-averaged CO2 concentration of 4.88 ± 0.07 %V/V was determined over four 
experimental repetitions. Implementation of Optiflow™ NHF therapy was found to provide a 
significant reduction of 0.25 %V/V in the time-averaged CO2 concentration at the lowest flow rate of 
10 LPM in comparison to natural breathing. With increasing NHF flow rates CO2 washout continued 
to increase, however only modest reductions in time-averaged CO2 concentration were seen at the 
upper flow rates tested with a minimum of 3.81 ± 0.11 % V/V observed at 80 LPM. The average CO2 
concentration observed during natural breathing was found to vary significantly across five unique 
airway models examined as did the efficacy of Optiflow™ NHF therapy at flow rates of 10 to 80 
LPM. As all other experimental parameters remained constant this was a result of anatomic 
differences alone and investigation found a reasonable relationship between natural breathing CO2 
concentration and the minimum larynx CSA. This relation did not however translate to the differences 
seen during NHF therapy. Though differences in therapy efficacy were seen across the five upper 




10 Conclusions and Future Work 
Static pressure measurements at multiple positions within the upper airway 06B model during natural 
breathing flows revealed the transient nature of the pressure wave had a form similar to and in phase 
with the breathing flow wave. In general the peak inspiratory and expiratory static pressures were 
seen to increase in magnitude as the measurement position neared the trachea. Pressure measurements 
at the nasopharynx suggested that the nasal passage resistance was equal for both flow directions. At 
the most inferior measurement positions at the entrance to the trachea the pressures indicated greater 
upper airway flow resistance for inspiration. With the use of NHF therapy mean and peak static 
pressures were seen to increase with increasing NHF flow rates at all measurement positions. A mean 
static gauge pressure of 300 Pa was observed at the superior trachea when breathing with 70 LPM 
NHF therapy, the maximum NHF flow rate employed. At the same measurement position the peak 
inspiratory pressure first assumed a positive value for a NHF flow rate of 30 LPM inferring that for 
this flow rate the work required to overcome the upper airway flow resistance was fulfilled by the 
NHF therapy. It was demonstrated that the transient static pressure profile at any flow rate of NHF 
therapy between 10 and 70 LPM could be reasonably well approximated as a function of the NHF 
flow rate and the natural breathing profile observed at the same measurement position. It was 
determined that the beneficial increases in inspiratory pressure and thus reductions in inspiratory work 
were accompanied by greater increases in expiratory pressures and work. It is subsequently thought 
likely that above some flow rate, dependant on the individual user, the detrimental pressure effects 
during expiration will outweigh the beneficial.Hot wire anemometry was employed to investigate the 
turbulence intensities of natural breathing flows passing through the centre of the left and right nares 
of two in vivo subjects and five in vitro airway models. Turbulence intensities measured in vivo and 
in vitro were similarly small during peak inspiration (~ 2 %) whilst peak expiration produced a large 
range from low (5 %) to high (46 %). Mean peak velocities observed at the nares also showed a larger 
range during expiration, with maximum in vitro values of 3.47 m/s and 2.50 m/s seen for expiration 
and inspiration respectively. Hot wire anemometry was further utilised to map the velocity and 
turbulence intensity profiles along an anterior to posterior traverse of the velopharynx of airway 06B 
during natural breathing flows. Peak expiration and inspiration velocity profiles showed mean 
velocities increasing toward the posterior, with maximum values of 3.82 and 3.02 m/s seen 
respectively. Peak inspiration turbulence intensities were relatively uniform and low along the 
traverse; however, peak expiration turbulence intensities rose to a high maximum of 55% near the 
anterior wall and subsequently declined in the posterior direction. The introduction of NHF therapy 
did not greatly affect the mean peak velocity profiles along the traverse, causing small changes to the 
peak expiration and inspiration maximums. NHF therapy also had little influence on the form of the 
turbulence intensity traverse profiles yet did produce a triple fold increase in the average turbulence 
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intensity across the centre of the velopharynx during peak inspiration. The minimal increases to the 
turbulence intensities during peak expiration from the use of NHF implied minor contribution to the 
mechanism of CO2 washout; however as only a single traverse was examined it is possible that in 
other regions the introduction of NHF therapy has a greater influence on turbulence intensity which 
does contribute to the washout effect. 
Two experimental methods were developed to investigate CO2 washout effects, the first mechanism 
of action proposed by Dysart et al. (2009) for the efficacy of NHF therapy. The first Experimental 
Method Version One took a non-physiologic approach, determining that the use of NHF therapy 
during breathing increased the rate of CO2 decay within the experimental model; however results 
lacked repeatability and this method was subsequently abandoned. Experimental Method Version 
Two employed a more realistic system with volumes to match an average adult respiratory system and 
a continuous flow of CO2 into the lung pump replicating the physiological process of CO2 diffusion 
into the lungs. Measurements of CO2 were taken just exterior to the lung volume, within the 
conducting airways, over many realistic breath cycles from which a time-averaged CO2 concentration 
was determined for each experiment. During natural breathing an average CO2 concentration of 4.88 ± 
0.07 %V/V was observed, with introduction of the lowest NHF flow rate at 10 LPM resulting in a 
reduction of 0.25 %V/V. At the highest tested NHF flow rate of 80 LPM the time-averaged CO2 
concentration had further declined to 3.81 ± 0.11 %V/V. The greatest reductions in concentration 
occurred within the first 30 LPM of NHF therapy, accounting for a 0.76 %V/V decrease from natural 
breathing, an interesting detail when taken into account with the transient pressure results which 
determined upper airway resistance to be overcome by 30 LPM NHF therapy. The time-averaged CO2 
concentrations observed during natural breathing and breathing with NHF therapy were found to have 
significant variation across five unique airway geometries tested. A reasonable linear relation was 
found between the airways’ minimum larynx cross-sectional areas and the natural breathing average 
CO2 concentrations; however this relation did not extend to CO2 concentrations observed during 
experiments with NHF therapy.  
10.1 Future Work 
Though this research has provided much new evidence to support the theories of positive airway 
pressure generation and CO2 washout of the upper airway during the use of Optiflow™ NHF therapy 
there is still scope for further investigations. It is suggested that the following work may be beneficial 
in furthering the research presented in this thesis to gain greater understanding of the mechanisms by 
which Optiflow™ NHF therapy provides respiratory support.  
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The transient pressure effects observed within the rigid airway model infer the generation of 
significant positive airway pressure with the use of NHF therapy; however the true in vivo pressure 
effects may vary significantly due to the compliance of the upper airway. By repeating the transient 
pressure experiments in a compliant model the influence of airway distensibility on the pressures 
achieved could be determined. As airway compliance is heterogeneous and complex a partially rigid 
model which replicates the compliance of the velopharynx, as achieved during the steady-state 
research of Cressy et al. (2011), may be useful in initial investigations, followed by replication of the 
compliant nasal vestibule. 
Use of multiple unique airway models during CO2 washout measurements revealed a dependence of 
the average natural breathing CO2 concentration and NHF washout efficacy on the upper airway 
geometry employed. For the case of natural breathing a tentative linear relation was found between 
the average CO2 concentration and the minimum larynx cross-sectional area, whilst no strong relation 
could be found for the average CO2 concentrations observed during NHF therapy. Further testing of 
CO2 washout within a greater number of unique airway models is suggested to provide greater 
population coverage, to determine the validity of the natural breathing relations proposed in this 
research and perhaps to find new relations to explain the differences in NHF therapy efficacy. 
Though this research has pioneered the measurement of CO2 washout effects, much more could be 
learnt by capturing the time-dependant CO2 concentration over a breath cycle with the use of a faster 
gas sensor. This would allow for more efficient experiments from which flow-averaged 
concentrations could be found. Concentration measurements within specific airway regions could then 
be performed from which the percentage washout of the upper airway and subsequently the effective 
reduction in dead space volume could be approximated. 
The five airway models employed in the current research all simulated a nasal-breathing flow path 
with the mouth closed as this is the mode of breathing recommended by FPH during the use of 
Optiflow™ NHF therapy. It is proposed that a mouth-open breathing mode during NHF therapy may 
actually increase the level of washout achieved as NHF flow administered by the nasal cannula would 
continuously flush the nasal cavity, nasopharynx, oropharynx and oral cavity, theoretically removing 
their entire volume from the anatomic dead space. Examination of this theory is suggested by 
performing CO2 washout experiments with a mouth-open upper airway model. 
From the pressure and CO2 washout results determined in this research the use of a NHF flow rate of 
30 LPM seems to provide an optimum positive airway pressure for mitigating the upper airway 
inspiratory resistance whilst also providing a large percentage of the attainable CO2 washout within 
the range of flow rates tested. Because of this it is suggested that a flow rate of 30 LPM may provide 
optimum respiratory support, particularly on account of the tradeoffs between the beneficial 
inspiratory and detrimental expiratory work effects caused by NHF therapy PAP generation. This 
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